

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/039736 A1

(51) International Patent Classification:

C07C 317/22 (2006.01) C07D 213/71 (2006.01)
C07C 311/29 (2006.01) C07D 213/34 (2006.01)
C07C 255/54 (2006.01) C07D 207/06 (2006.01)
C07C 235/46 (2006.01) C07D 213/55 (2006.01)
C07C 59/66 (2006.01) C07D 265/06 (2006.01)
C07C 317/12 (2006.01)

Road, Loughborough, Leicestershire LE11 5RH (GB).
PATEL, Anil [GB/G]; AstraZeneca R & D Charnwood,
Bakewell Road, Loughborough, Leicestershire LE11 5RH
(GB).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-
traZeneca AB, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/GB2006/003689

(22) International Filing Date: 5 October 2006 (05.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0520323.7 6 October 2005 (06.10.2005) GB
0608299.4 27 April 2006 (27.04.2006) GB

(71) Applicant (for all designated States except MG, US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, Greater London, Lon-
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LUKER, Timothy**,
Jon [GB/GB]; AstraZeneca R & D Charnwood, Bakewell
Road, Loughborough, Leicestershire LE11 5RH (GB).
MOHAMMED, Rukhsana, Tusneem [GB/GB]; As-
traZeneca R & D Charnwood, Bakewell Road, Loughbor-
ough, Leicestershire LE11 5RH (GB). **THOM, Stephen**
[GB/GB]; AstraZeneca R & D Charnwood, Bakewell

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT,
LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

NOVEL COMPOUNDS

The present invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.


EPA 1 170 594 discloses methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D₂, a ligand for orphan receptor CRTH₂. GB 1356834 discloses a series of compounds said to possess anti-inflammatory, analgesic and antipyretic activity. It has been found that certain phenylacetic acids are active at the CRTH₂ receptor, and as a consequence are expected to be potentially useful for the treatment of various respiratory diseases, including asthma and COPD.

Phenyl acetic acids which bind to CRTh₂ are disclosed in WO2004/058164. These compounds have dual activity at both the CRTh₂ and DP receptors. The compounds disclosed in WO2004/058164 have embedded amino derived substituents which could potentially be metabolised to give mutagenic anilines.

Related compounds are disclosed in EP91402638, and are said to be useful in the treatment of various inflammatory and/or allergic diseases, particularly asthma, allergic rhinitis, arthritis and inflammation.

The present invention relates to compounds that bind selectively to the CRTH₂ receptor. These phenyl acetic acids also do not contain any potentially toxic embedded anilines and are therefore advantageous as potential drug molecules.

In a first aspect the invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:



in which:

A and D are independently selected from hydrogen, halogen, CN, OR³, S(O)nR³ (where n is 0, 1 or 2), nitro, aryl, heteroaryl, C₃₋₈cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by halogen atoms;

E is O, S, NR⁶ or CR¹R²;

5 V is N or C(H);

W is nitrogen or W is a carbon atom substituted by hydrogen, halogen, CN, SO₂R⁹,

or

C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms);

X is nitrogen or X is a carbon atom substituted by hydrogen, halogen, CN, SO₂R⁹,

10 or

C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms);

Y is selected from hydrogen, CN, halogen, C₁₋₆ alkyl (the latter being optionally substituted by one or more halogen atoms);

Z is selected from hydrogen, halogen, CN, SO₂NR⁴R⁵, CONR⁴R⁵, COR⁶, CO₂R⁶,
15 SO₂R⁹ or OR⁹;

R¹ and R² independently represent a hydrogen atom, halogen, or a C₁₋₆alkyl group;

or

R¹ and R² together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR⁶ and itself optionally substituted by one or more C₁₋₃ alkyl or halogen;
20

R³ is hydrogen, C₁₋₆ alkyl (optionally substituted by halogen or NR⁴R⁵) or SO₂R⁷;

R⁴ and R⁵ independently represent hydrogen, C₃₋₈ cycloalkyl or C₁₋₆alkyl the latter two groups being optionally substituted by one or more substituents independently selected from halogen, CN, C₃₋₇ cycloalkyl, C₁₋₆ alkyl, OR³ and NR⁷R⁸, aryl, heteroaryl, S(O)_nR⁹ (where n = 0,1 or 2), CONR⁷R⁸, NR³COR¹⁰, SO₂NR⁴R⁵ and NR³SO₂R⁹;
25

or

R⁴ and R⁵ together with the nitrogen atom to which they are attached can form a 3-8 membered saturated ring optionally containing one or more atoms selected from O, N, S(O)_n (where n = 0,1 or 2), NR³, and itself optionally substituted by one or more halogen, OR³, C₃₋₈ cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by one or more halogen;
30

R⁶ represents aryl, heteroaryl, C₃₋₈ cycloalkyl or C₁₋₆alkyl all of which being optionally substituted by one or more substituents independently selected from halogen, C₃₋₇ cycloalkyl, C₁₋₆ alkyl, OR³, CN, NR⁷R⁸, aryl, heteroaryl, S(O)_nR⁹ (where n = 0, 1 or 2), CONR⁷R⁸, NR³COR¹⁰, SO₂NR⁴R⁵ and NR³SO₂R⁹;

R⁷ independently represents a hydrogen atom or C₁₋₆ alkyl (the alkyl group can be optionally substituted by one or more halogen atoms);

R⁸ is hydrogen, C₁₋₄ alkyl, -COC₁₋₄ alkyl, CO₂C₁₋₄alkyl or CONR⁶C₁₋₄alkyl;

R⁹ represents aryl, heteroaryl, C₃₋₇ cycloalkyl or C₁₋₆alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C₃₋₇ cycloalkyl, aryl, heteroaryl, OR⁶ and NR¹⁰R¹¹, S(O)_nR⁶ (where n = 0, 1 or 2), CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁴R⁵ and NR⁶SO₂R⁷;

R¹⁰ and R¹¹ independently represent aryl or heteroaryl, hydrogen, C₃₋₇ cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C₃₋₇ cycloalkyl, aryl, heteroaryl, OH, OR⁹ and NR⁴R⁵, S(O)_nR⁶ (where n = 0, 1 or 2), CONR⁴R⁵, NR⁶COR⁷, SO₂NR⁴R⁵ and NR⁶SO₂R⁷;

or

R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)_n (where n = 0, 1 or 2), NR⁸, and itself optionally substituted by halogen or C₁₋₃ alkyl, provided that:

- A and D cannot both be hydrogen;
- A and D cannot be aryl substituted in the *para*-position by -S(O)_n-, where n is 0, 1 or 2;
- when V, W and X are all carbon then all of the substituents on the phenyl ring (V, W, X, Y and Z) cannot be hydrogen.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched and maybe optionally substituted by one or more halogen atoms.

Examples of aryl include phenyl and naphthyl.

Heteroaryl is defined as a 5-7 member aromatic ring or can be 6,6- or 6,5-fused bicyclic ring optionally containing one or more heteroatoms selected from N, S, O. The

bicyclic ring may be linked through carbon or nitrogen and may be attached through the 5 or 6 membered ring and can be fully or partially saturated.

Examples include but are not limited to pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, furan, isoxazole, pyrrole, isothiazole and azulene, naphthyl, indene, quinoline, isoquinoline, indole, indolizine, benzo[b]furan, benzo[b]thiophene, 1H-indazole, benzimidazole, benzthiazole, benzoxazole, purine, 4H-quinolizine, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, pteridine, quinolone and 1,2-methylenedioxy benzene.

Aryl or heteroaryl groups as substituents can be optionally substituted by one or more substituents independently selected from halogen, CN, OR⁷, SO₂R³, CONR⁷R⁸, SO₂NR⁴R⁵, C₃₋₈ cycloalkyl or C₁₋₆ alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, OR³.

Preferably A is hydrogen, halogen, CN, OR³, aryl, heteroaryl or C₁₋₆alkyl, the latter group being optionally substituted by one or more halogen atoms;

More preferably A is hydrogen, halogen or C₁₋₆alkyl, the latter group being optionally substituted by one or more halogen atoms;

Preferably D is hydrogen, halogen or C₁₋₆alkyl, the latter group being optionally substituted by one or more halogen atoms;

Preferably where D is not hydrogen then A is hydrogen; where A is not hydrogen then D is hydrogen;

Preferably E is oxygen or sulfur; more preferably E is oxygen;

Preferably V is C(H);

Preferably W is a carbon atom substituted by hydrogen, halogen, CN or C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms); more preferably W is a carbon atom substituted by hydrogen, halogen or C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms); most preferably W is C(H);

Preferably X is a carbon atom substituted by hydrogen or halogen; more preferably X is C(H);

Preferably Y is halogen, cyano or C₁₋₃ alkyl optionally substituted by halogen atoms;

Preferably Z is selected from SO₂R⁹, SO₂NR⁴R⁵, CONR⁴R⁵ or COR⁶;

More preferably Z is SO₂R⁹;

Preferably R^1 and R^2 are both hydrogen, or one of R^1 or R^2 is methyl and the other is hydrogen. More preferably R^1 and R^2 are both hydrogen;

Preferred compounds of the invention include:

- {4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
- 5 {4-chloro-3-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-[4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
- 2-{4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}propanoic acid;
- 10 {4-chloro-3-{2-chloro-4-[(dimethylamino)sulfonyl]phenoxy}phenyl}acetic acid;
- [4-chloro-3-(3-cyanophenoxy)phenyl]acetic acid;
- {4-chloro-3-[2-fluoro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-[4-(ethylsulfonyl)-2-fluorophenoxy]phenyl}acetic acid;
- {4-chloro-3-[2-cyano-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
- 15 {4-chloro-3-[2-cyano-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-[4-(methylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-[2-cyano-5-(trifluoromethyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-{2-fluoro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl}acetic acid;
- [3-(4-benzoyl-2-fluorophenoxy)-4-chlorophenyl]acetic acid;
- 20 {4-chloro-3-{2-chloro-4-[(isobutylamino)carbonyl]phenoxy}phenyl}acetic acid;
- {3-chloro-5-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
- {3-chloro-5-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
- {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-fluorophenyl}acetic acid;
- {3-fluoro-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
- 25 {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-4-fluorophenyl}acetic acid;
- {4-fluoro-3-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
- {4-chloro-3-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
- [3-[2-chloro-4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
- [3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
- 30 {3-chloro-5-[2-fluoro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
- {3-chloro-5-[2-cyano-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
- {3-chloro-5-[2-chloro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;

- {3-chloro-5-[4-(ethylsulfonyl)-2-fluorophenoxy]phenyl}acetic acid;
{3-chloro-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
[3-{2-fluoro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
(3-chloro-5-{4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
5 (3-chloro-5-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
{3-chloro-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
{3-chloro-5-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
[3-[2-fluoro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
[3-[2-chloro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
10 [3-[4-(ethylsulfonyl)-2-fluorophenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
[3-[2-cyano-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
[3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
{3-[4-(benzylsulfonyl)-2-chlorophenoxy]-5-chlorophenyl}acetic acid;
{3-chloro-5-[4-(phenylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
15 {3-chloro-5-[2-cyano-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
{3-[4-(benzylsulfonyl)-2-fluorophenoxy]-5-chlorophenyl}acetic acid;
(3-chloro-5-{2-fluoro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
{3-[4-(benzylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-chlorophenyl}acetic acid;
(3-chloro-5-{2-fluoro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
20 (3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid;
2-[3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid;
2-[3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid;
2-[3-[2-chloro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid;
25 2-[3-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]propanoic acid;
(3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid;
{3-bromo-5-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methylphenyl}acetic acid;
30 methyl 3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-cyanobenzoate;
[3-[(2-chloro-4-(ethylsulfonyl)phenyl)thio]-5-(trifluoromethyl)phenyl]acetic acid;
{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methoxyphenyl}acetic acid;

- [3-{2-chloro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 [3-{{3-methyl-5-(phenylsulfonyl)pyridin-2-yl}oxy}-5-(trifluoromethyl)phenyl]acetic acid;
 [3-{2-chloro-4-(morpholin-4-ylsulfonyl)phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 [3-(4-benzoyl-2-chlorophenoxy)-5-(trifluoromethyl)phenyl]acetic acid;
 5 [3-{2-chloro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 {3-bromo-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 [3-{2-fluoro-4-[(4-fluorophenyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 {3-chloro-5-[4-(ethylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid;
 {3-chloro-5-[5-chloro-2-fluoro-4-(pyrrolidin-1-ylcarbonyl)phenoxy]phenyl}acetic acid;
 10 {3-cyano-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 (3-chloro-5-{2-fluoro-4-[(4-fluorophenyl)sulfonyl]phenoxy}phenyl)acetic acid;
 (3-chloro-5-{[2-cyano-4-(ethylsulfonyl)phenyl]thio}phenyl)acetic acid;
 (3-chloro-5-{[4-(ethylsulfonyl)-2-(trifluoromethyl)phenyl]thio}phenyl)acetic acid;
 (3-chloro-5-{[2-fluoro-4-(phenylsulfonyl)phenyl]thio}phenyl)acetic acid;
 15 [3-(4-benzoyl-3,5-difluorophenoxy)-5-chlorophenyl]acetic acid;
 {3-chloro-5-[2-chloro-4-(4-fluorobenzoyl)phenoxy]phenyl}acetic acid;
 {3-[2-fluoro-4-(phenylsulfonyl)phenoxy]-5-methylphenyl}acetic acid;
 {3-ethyl-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 [3-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 20 [3-[2-cyano-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 {5-[2-chloro-4-(ethylsulfonyl)phenoxy]biphenyl-3-yl}acetic acid;
 {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-pyridin-2-ylphenyl}acetic acid;
 {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-[2-(dimethylamino)ethoxy]phenyl}acetic acid
 [3-{2-chloro-4-[(pyridin-2-ylmethyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic
 25 acid
 and pharmaceutically acceptable salts thereof.


Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and
 30 mixtures thereof also form an aspect of the present invention.

The compound of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium,

potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, *tertiary*butylamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups in the starting reagents or intermediate compound may need to be protected by protecting groups. Thus, the preparation of the compound of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 3rd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1999).

Compounds of formula (I) can be prepared by reaction of a compound of formula (II) with a compound of formula (III) as outlined in Scheme 1:




Scheme 1

In which A, D, E, V, W, X, Y, Z, R¹ and R² are as defined in formula (I) or are protected derivatives thereof. L¹ is a leaving group such as halogen, preferably fluoro or chloro. J is alkyl for example methyl, ethyl or *tertiary* butyl. The reaction is carried out at elevated temperatures in a polar solvent such as NMP or DMF in the presence of a base, such as cesium carbonate or the like. The ester group is subsequently removed using a base such as sodium hydroxide in a suitable organic solvent such as methanol, ethanol or THF.

Compounds of formula (I) can also be prepared directly by reacting compounds of formula (IV) with compounds of formula (III).

Compounds of formula (II) and formula (IV) can be prepared as outlined in Scheme 2:



5


Scheme 2

In which A, D and Y, are as defined in formula (I) or are protected derivatives thereof. J is as defined for compounds of formula (II). R^{21} is C_{1-3} alkyl, such as methyl.

Hydrolysis of the ester group J can be carried out using routine procedures, for example treatment of methyl and ethyl esters with aqueous sodium hydroxide, and treatment of tert-butyl esters with acids such as trifluoroacetic acid.

10

Compounds of formula (IV) in which E is O can be prepared as outlined in Scheme 2A:




Scheme 2A

In which A and D are as defined in formula (I) or are protected derivatives thereof. L^2 is a chlorine or fluorine. L^3 is a suitable leaving group such as chlorine, bromine or mesylate.

The group L^2 in compounds of formula (VIII) is displaced using sodium methoxide in a suitable solvent such as DMPU or HMPA. The benzoic acid group is then reduced to the alcohol using lithium aluminium hydride or borane in a suitable solvent such as THF. The leaving group L^3 can be introduced by reacting compounds of formula (X) with thionyl chloride or phosphorus tribromide or by converting to the mesylate by reacting compounds of formula (X) with methane sulfonyl chloride in the presence of a base such as triethylamine in a suitable organic solvent such as dichloromethane. The group L^3 is then displaced with sodium cyanide in a polar solvent such as DMF at elevated temperatures to give compounds of formula (XII). The nitrile can be hydrolysed to the acid and the group Y deprotected in one step using aqueous HBr in acetic acid at elevated temperatures.

Certain compounds of formula (VIII) are commercially available.

Some compounds of formula (III) in which one of the substituents is SO_2R^9 can be prepared by general reaction Scheme 3:




5

Scheme 3

In which L^1 , V , W , X and Y and R^9 are as defined in formula (III) or are protected derivatives thereof. The diazotisation is carried out at elevated temperatures, such as 60°C in a suitable organic solvent for example acetonitrile. The corresponding sulfide is oxidised using MCPBA or oxone as the oxidising agent in a suitable solvent, for example, dichloromethane.

10

Certain compounds of formula (III) containing a sulfone moiety can also be prepared as outlined in reaction Scheme 4:



15


Scheme 4

In which L^1 , V , W , X , Y and R^9 are as defined in formula (III) or protected derivatives thereof.

L^4 is a suitable leaving group such as halogen, preferably iodide, bromide or chloride. The thiol is reacted with compounds of formula (XIII) and then oxidised using a suitable oxidising agent such as MCPBA or oxone.

20


Certain compounds of formula (III) in which Z is COR^6 can be prepared as outlined in Scheme 5:



Scheme 5.

In which L^1 , V, W, X, Y and R^6 are as defined in formula (III) or protected derivatives thereof. Compounds of formula (XIV) can undergo a Friedel-Crafts acylation using standard conditions, for example heating in the presence of a suitable Lewis Acid such as iron (III) chloride. Compounds of formula (XIV) are commercially available or are prepared using known literature procedures.


Certain compounds of formula (III) in which Z is $SO_2NR^4R^5$ or $CONR^4R^5$ are prepared as outlined in Scheme 6:



Scheme 6

In which L^1 , V, W, X, Y, R^4 and R^5 are as defined in formula (III) or are protected derivatives thereof and in which J is C(O) or SO_2 and L is a suitable leaving group such as halogen or alternatively L is hydroxy. The coupling is carried out using standard amide or sulphonamide coupling procedures. For example, where L is halogen the reaction can be carried out by stirring in a suitable solvent such as DCM in the presence of a suitable base such as Hunigs base or triethylamine. Alternatively where L is hydroxy the reaction can be carried out using a suitable coupling agent such as PyBOP or HATU or CDI with a suitable base such as Hunigs base or DBU in a suitable solvent such as DCM or THF. Compounds of formula (XV) are commercially available or are prepared using known literature procedures.

Compounds of formula (IV) where E is S can be prepared from compounds of formula (IV) where E is O as outlined in Scheme 7:




Scheme 7.

In which A and D are as defined in formula (I) or are protected derivatives thereof.

- 5 Compounds of formula (IV) undergo coupling with dimethylthiocarbamoyl chloride and subsequently rearrange on heating at elevated temperatures in a suitable solvent such as tetradecane or diphenylether. Compounds of formula (II) are obtained following hydrolysis with a suitable base such as sodium hydroxide.

- 10 Compounds of formula (I) in which A is CN, C₁₋₆ alkyl, aryl or heteroaryl can be prepared as outlined in Scheme 8:




Scheme 8.

- 15 In which D, E, V, W, X, Y, Z, R¹ and R² are as defined in formula (I) or are protected derivatives thereof. The reaction is carried out using standard metal-catalysed coupling techniques. For example, the coupling reactions can be carried out by reacting compounds of formula (XVI) with an appropriate activated palladium catalyst such as bisdiphenylphosphino ferrocene palladium (II) and with the boronic acid adduct of A in the presence of a suitable base such as sodium carbonate or potassium carbonate or cesium carbonate in a suitable solvent such as toluene, THF or dioxane. The reactions are usually
- 20 carried out at elevated temperatures, for example 80 °C. Alternatively, the coupling reactions can be carried out by reacting compounds of formula (XVI) with an appropriate

activated palladium catalyst such as bisdiphenylphosphinoferrocene palladium (II) and with the zinc adduct of A at elevated temperatures, for example 80 °C, in a suitable solvent such as toluene, THF or dioxane.

Certain compounds of formula (I) in which A is OR³ can be prepared according to

5 Scheme 9:



Scheme 9.

In which D, E, V, W, X, Y, Z, R¹ and R² are as defined in formula (I) or are protected derivatives thereof. E¹ is as defined in formula (II). L² is a suitable leaving group such as halogen or an activated alcohol such as mesylate or tosylate. Compounds of formula (I) are coupled with compounds of formula (XVIII) using a suitable base such as sodium carbonate or potassium carbonate or cesium carbonate in a suitable solvent such as acetonitrile or DMF. The ester group is subsequently removed as described above.

15 In a further aspect, the present invention provides the use of a compound of formula (I), a prodrug, pharmaceutically acceptable salt or solvate thereof for use in therapy.

The compounds of formula (I) or pharmaceutically acceptable salts thereof have activity as pharmaceuticals, in particular as modulators of CRTh2 receptor activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of PGD₂ and its metabolites.

A compound of the invention, or a pharmaceutically acceptable salt thereof, can be used in the treatment of:

1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary

disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;

2. bone and joints: arthritides associated with or including osteoarthritis/osteoarthritis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondyloarthropathy; septic arthritis and other infection-related arthropathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; drug-induced arthralgias, tendonitis, and myopathies;

3. pain and connective tissue remodelling of musculoskeletal disorders due to injury [for example sports injury] or disease: arthritides (for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy), other joint disease (such as intervertebral disc degeneration or temporomandibular joint degeneration), bone remodelling disease (such as osteoporosis, Paget's disease or osteonecrosis), polychondritis, scleroderma, mixed
5 connective tissue disorder, spondyloarthropathies or periodontal disease (such as periodontitis);
4. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis;
10 scborrhoec dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective;
15 panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;
5. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic
20 ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;
6. gastrointestinal tract: glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, and food-related allergies which may have effects remote from the gut (for example migraine,
25 rhinitis or eczema);
7. abdominal: hepatitis, including autoimmune, alcoholic and viral; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic;
8. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer;
30 acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; erectile dysfunction (both male and female);

9. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;
10. CNS: Alzheimer's disease and other dementing disorders including CJD and
5 nvCJD; amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; acute and chronic pain (acute, intermittent or persistent, whether of central or peripheral origin) including visceral pain, headache, migraine, trigeminal neuralgia, atypical facial pain, joint and bone pain, pain arising from cancer and tumor invasion, neuropathic pain syndromes including
10 diabetic, post-herpetic, and HIV-associated neuropathies; neurosarcoidosis; central and peripheral nervous system complications of malignant, infectious or autoimmune processes;
11. other auto-immune and allergic disorders including Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopenic
15 purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome;
12. other disorders with an inflammatory or immunological component; including acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and paraneoplastic syndromes;
13. cardiovascular: atherosclerosis, affecting the coronary and peripheral circulation;
20 pericarditis; myocarditis, inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins;
14. oncology: treatment of common cancers including prostate, breast, lung, ovarian,
25 pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,
15. gastrointestinal tract: Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, microscopic colitis, indeterminant colitis,
30 irritable bowel disorder, irritable bowel syndrome, non-inflammatory diarrhea, food-

related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema.

16. Diseases associated with raised levels of PGD₂ or its metabolites.

Thus, the present invention provides a compound of formula (I), or a
5 pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

Preferably the compounds of the invention are used to treat diseases in which the chemokine receptor belongs to the CRTh2 receptor subfamily.

Particular conditions which can be treated with the compounds of the invention are
10 asthma, rhinitis and other diseases in which raised levels of PGD₂ or its metabolites. It is preferred that the compounds of the invention are used to treat asthma.

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

15 In a further aspect, the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy in combination with drugs used to treat asthma and rhinitis (such as inhaled and oral steroids, inhaled β 2-receptor agonists and oral leukotriene receptor antagonists).

20 The invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.

25 In particular, for the treatment of the inflammatory diseases such as (but not restricted to) rheumatoid arthritis, osteoarthritis, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), psoriasis, and inflammatory bowel disease, the compounds of the invention may be combined with agents listed below.

Non-steroidal anti-inflammatory agents (hereinafter NSAIDs) including non-
30 selective cyclo-oxygenase COX-1 / COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid,

indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin); selective COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumaprocoxib, parecoxib and etoricoxib); cyclo-oxygenase inhibiting nitric oxide donors (CINODs); glucocorticosteroids (whether administered by topical, oral, 5 intramuscular, intravenous, or intra-articular routes); methotrexate; leflunomide; hydroxychloroquine; d-penicillamine; auranofin or other parenteral or oral gold preparations; analgesics; diacerein; intra-articular therapies such as hyaluronic acid derivatives; and nutritional supplements such as glucosamine.

The present invention still further relates to the combination of a compound of the 10 invention, or a pharmaceutically acceptable salt thereof, together with a cytokine or agonist or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma-interferons; insulin-like growth factor type I (IGF-1); interleukins (IL) including IL1 to 17, and interleukin antagonists or inhibitors such as anakinra; tumour necrosis factor alpha 15 (TNF- α) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab, and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular-weight agents such as pentoxifylline.

In addition the invention relates to a combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a monoclonal antibody targeting B- 20 Lymphocytes (such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax Il-15).

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a modulator of chemokine receptor function such as an antagonist of CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, 25 CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an inhibitor of matrix 30 metalloprotease (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8),

collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-9 and MMP-12, including agents such as doxycycline.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a leukotriene biosynthesis
5 inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2-alkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-
10 cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK-886, and BAY x 1005.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a receptor antagonist for leukotrienes (LT) B₄, LTC₄, LTD₄, and LTE₄. selected from the group consisting of the
15 phenothiazin-3-1s such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a phosphodiesterase (PDE)
20 inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a histamine type 1 receptor
25 antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a proton pump inhibitor (such
30 as omeprazole) or a gastroprotective histamine type 2 receptor antagonist.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an antagonist of the histamine type 4 receptor.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an alpha-1/alpha-2
5 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethyllorepinephrine
10 hydrochloride.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an anticholinergic agents including muscarinic receptor (M1, M2, and M3) antagonist such as atropine, hyoscine, glycopyrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide,
15 pirenzepine or telenzepine.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, or pirbuterol, or a chiral
20 enantiomer thereof.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a chromone, such as sodium cromoglycate or nedocromil sodium.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a glucocorticoid, such as
25 flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an agent that modulates a
30 nuclear hormone receptor such as PPARs.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an immunoglobulin

(Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and another systemic or topically-applied anti-inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and combinations of aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse transcriptase inhibitor such as nevirapine or efavirenz.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist; a lipid lowering agent such as a statin or a fibrate; a modulator of blood cell morphology such as pentoxifylline; thrombolytic, or an anticoagulant such as a platelet aggregation inhibitor.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole, pramipexole, a MAOB inhibitor such as selegine and rasagiline, a COMT inhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptake inhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist or an inhibitor of neuronal nitric oxide

synthase), or an anti-Alzheimer's drug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor, propentofylline or metrifonate.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an agent for the treatment of acute or chronic pain, such as a centrally or peripherally-acting analgesic (for example an opioid or derivative thereof), carbamazepine, phenytoin, sodium valproate, amitriptyline or other anti-depressant agent-s, paracetamol, or a non-steroidal anti-inflammatory agent.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.

A compound of the present invention, or a pharmaceutically acceptable salt thereof, can also be used in combination with an anti-osteoporosis agent including a hormonal agent such as raloxifene, or a bisphosphonate such as alendronate.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a: (i) tryptase inhibitor; (ii) platelet activating factor (PAF) antagonist; (iii) interleukin converting enzyme (ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitors including VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor such as an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, for example Gefitinib or Imatinib mesylate), a serine / threonine kinase (such as an inhibitor of a MAP kinase such as p38, JNK, protein kinase A, B or C, or IKK), or a kinase involved in cell cycle regulation (such as a cyclin dependent kinase); (viii) glucose-6 phosphate dehydrogenase inhibitor; (ix) kinin-B.sub1. - or B.sub2. -receptor antagonist; (x) anti-gout agent, for example colchicine; (xi) xanthine oxidase inhibitor, for example allopurinol; (xii) uricosuric agent, for example probenecid, sulfinpyrazone or benzbromarone; (xiii) growth hormone secretagogue; (xiv) transforming growth factor (TGF β); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor for example basic fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) tachykinin NK.sub1. - or NK.sub3. receptor antagonist such as NKP-608C, SB-233412 (talnetant) or D-4418; (xx) elastase inhibitor such as UT-77 or ZD-0892; (xxi) TNF-alpha converting enzyme inhibitor (TACE); (xxii) induced nitric oxide synthase (iNOS) inhibitor; (xxiii) chemoattractant

receptor-homologous molecule expressed on TH2 cells, (such as a CRTH2 antagonist);
(xxiv) inhibitor of P38; (xxv) agent modulating the function of Toll-like receptors (TLR),
(xxvi) agent modulating the activity of purinergic receptors such as P2X7; or (xxvii)
inhibitor of transcription factor activation such as NFkB, API, or STATS.

5 A compound of the invention, or a pharmaceutically acceptable salt thereof, can
also be used in combination with an existing therapeutic agent for the treatment of cancer,
for example suitable agents include:

(i) an antiproliferative/antineoplastic drug or a combination thereof, as used in medical
oncology, such as an alkylating agent (for example cis-platin, carboplatin,
10 cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a
nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like
5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea,
gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as
adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C,
15 dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as
vincristine, vinblastine, vindesine or vinorelbine, or a taxoid such as taxol or taxotere); or a
topoisomerase inhibitor (for example an epipodophyllotoxin such as etoposide, teniposide,
amsacrine, topotecan or a camptothecin);

(ii) a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene,
20 raloxifene, droloxifene or idoxifene), an oestrogen receptor down regulator (for example
fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or
cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin,
leuporelin or buserelin), a progestogen (for example megestrol acetate), an aromatase
inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of
25 5 α -reductase such as finasteride;

(iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor
like marimastat or an inhibitor of urokinase plasminogen activator receptor function);

(iv) an inhibitor of growth factor function, for example: a growth factor antibody (for
example the anti-erbB2 antibody trastuzumab, or the anti-erbB1 antibody cetuximab
30 [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine
kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR
family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-

morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), *N*-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-*N*-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), an inhibitor of the platelet-derived growth factor family, or an inhibitor of the hepatocyte growth factor family;

(v) an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin $\alpha v \beta 3$ function or an angiostatin);

(vi) a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213;

(vii) an agent used in antisense therapy, for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense;

(viii) an agent used in a gene therapy approach, for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or

(ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of CRTh2 receptor activity is beneficial.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention still further provides a method of treating diseases mediated by PGD2 or its metabolites wherein the prostanoïd binds to its receptor (especially CRTh2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, as hereinbefore defined.

The invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

The compound of formula (I), prodrugs and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as herein before defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.


The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal

administration in the form of suppositories or transdermally. Preferably the compound of the invention is administered orally.

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- 5 (i) when given, ^1H NMR data is quoted in the form of δ values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard;
- (ii) mass spectra (MS): generally only ions which indicate the parent mass are reported, (MM) = MultiMode;
- 10 (iii) the title compounds of the examples and methods were named using the ACD/name and ACD/name batch (version 6.0) from Advanced Chemical Development Inc, Canada;
- (iv) unless stated otherwise, reverse phase HPLC (RPHPLC) was conducted using a Symmetry, NovaPak or Ex-Terra reverse phase silica column;
- (v) solvents were dried with MgSO_4 or Na_2SO_4 ;
- 15 (vi) reactions are carried out at room temperature unless otherwise stated;
- (vii) the following abbreviations are used:

	aq.	Aqueous
	BuLi	Butyl lithium
20	HCl	Hydrochloric acid
	NBS	N-Bromosuccinimide
	DCM	Dichloromethane
	DMF	<i>N,N</i> -dimethylformamide
	Ether	Diethyl ether
25	EtOAc	Ethyl acetate
	HBr	Hydrogen bromide
	MeI	Methyl iodide
	NMP	1-Methyl-2-pyrrolidone
	THF	Tetrahydrofuran
30	MCPBA	3-Chloroperoxybenzoic acid (Aldrich 77% max)
	RT	Room temperature

Example 1**4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenylacetic acid****(i) 4-(Bromomethyl)-1-chloro-2-methoxybenzene**

- 2-Chloro-5-methylphenol (20 g), K_2CO_3 (30 g), acetone (200 ml) and methyl iodide (9.4 ml) were charged to a flask and stirred for 24 h. The solvent was removed under reduced pressure and the residue partitioned between ether and water. The organics were separated, washed with 2 M sodium hydroxide, water, dried ($MgSO_4$) and evaporated under reduced pressure. The residue was dissolved in EtOAc, then NBS (25 g) and benzoyl peroxide (0.5 g) was added and the reaction mixture irradiated with a halogen lamp for 3 h. The solvent was removed under reduced pressure and the residue was purified by flash column chromatography (eluent isohexane) to give the subtitle compound (30 g) used directly without further purification or characterisation.

(ii) (4-Chloro-3-methoxyphenyl)acetic acid

- The product from step (i), DMF (200 ml) and sodium cyanide (20 g) were charged to a flask and stirred for 2 h at RT. The residue was partitioned between ether and water; the organics were separated, washed with water, dried ($MgSO_4$) and evaporated under reduced pressure. Potassium hydroxide (40 g in water) was added and the mixture heated at reflux for 24 h. The reaction mixture was cooled to RT and extracted with ether. The aq layer was acidified to pH 1 with concentrated HCl and extracted with ethyl acetate. The organic layer was washed with water, dried ($MgSO_4$) and evaporated under reduced pressure. The residue was triturated with isohexane/ether, and then filtered to give the subtitle compound (12.2 g).

(iii) (4-Chloro-3-hydroxyphenyl)acetic acid

- The product from step (ii) (12.2 g), HBr (48 % aq.) and acetic acid (10 ml) were charged to a flask and heated at reflux for 24 h, cooled then evaporated under reduced pressure. The

residue was triturated with ether/isohehexane, and then filtered to give the subtitle compound (10.6 g).

¹H NMR CDCl₃-d₆: δ 7.32 (1H, d), 6.85 (1H, s), 6.82 (1H, d), 3.9 (3H, s), 3.63 (2H, s).

5 (iv) **Ethyl (4-chloro-3-hydroxyphenyl)acetate**

The product of step (iii) (4 g) was added to a solution of acetyl chloride (10 ml) in ethanol (40 ml). The mixture was stirred for 1 h at RT then evaporated under reduced pressure.

The residue was purified by flash column chromatography (eluent 2:1 isohehexane/ EtOAc) to give the subtitle compound (4.4 g).

10

(v) **ethyl {4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetate**


The product from step (iv) (4.4 g), 3-chloro-4-fluorophenyl methyl sulfone (4.27 g), cesium carbonate (6.5 g) and NMP (40 ml) were charged to a flask and stirred at 90 °C for 2 h. The reaction was diluted with water, extracted with EtOAc, dried (MgSO₄) and
15 evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 2:1 isohehexane/ ether) to give the subtitle compound (3.6 g).
MS: ESI-ve 401 (M-H) .

(vi) **{4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid**

20 Sodium hydroxide (0.72 g) in water (40 ml) was added to the product from step (v) (3.6 g) in THF (40 ml) and stirred at RT overnight. The reaction was quenched with 2M HCl, extracted with EtOAc, dried (MgSO₄) and evaporated under reduced pressure. The residue was recrystallised from EtOAc/isohehexane to give the subtitle compound (2.6 g).

¹H NMR DMSO-d₆: δ 12.46 (1H, s), 8.15-8.14 (1H, s), 7.84 (1H, d), 7.63-7.59 (1H, d),
25 7.28-7.24 (2H, m), 6.93 (1H, d), 3.64 (2H, s), 3.27 (3H, s).

MS: ESI-ve 372 (M-H)

Example 2**{4-chloro-3-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid****(i) 4-fluoro-3-(trifluoromethyl)phenyl methylsulfide**

5 Isoamyl nitrite (1.13 ml) was added to a solution of diethyldisulfide (0.69 ml) 4-fluoro-3-(trifluoromethyl)aniline (1 g) in acetonitrile (50 ml). The solution was heated at reflux at 60 °C for 2 h, and then evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 2:1 isohexane/ ether) to give the subtitle compound (0.57 g).

10 ¹H NMR CDCl₃-d₆: δ 7.41 (2H, m), 7.10 (1H, t), 2.5 (3H, s).

(ii) 4-fluoro-3-(trifluoromethyl)phenyl methylsulfone

MCPBA (1.1 g) was added to a solution of the product from step (i) (0.57 g) in DCM (20 ml) and stirred overnight. The solution was washed with aq sodium metabisulfite. The organic phase was dried (MgSO₄) and evaporated under reduced pressure, to give the subtitle compound (0.4 g).


¹H NMR CDCl₃-d₆: δ 8.26-8.18 (2H, dd), 7.44 (1H, t), 3.10 (3H, s).

(iii) {4-chloro-3-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid

20 The product of step (ii) (150 mg), the product of example 1 step (iii) (125 mg), cesium carbonate (437 mg) and NMP (10 ml) were charged to a flask and heated for 10 h at 80 °C. The solution was acidified and extracted with ethyl acetate. The organic extracts were dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by RPHPLC to give the title compound (117 mg).

25 ¹H NMR DMSO-d₆: δ 12.48 (1H, s), 8.27 (1H, s), 8.16-8.14 (1H, d), 7.66-7.64 (1H, d), 7.33-7.31 (2H, m), 6.96 (1H, d), 3.67 (2H, s), 3.31 (3H, s).

MS: APCI-ve 407 (M-H).

Example 3**{4-chloro-3-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid****(i) 3-chloro-4-fluorophenyl ethyl sulfone**

3-chloro-4-fluorobenzenethiol (10 g), iodoethane (4.9 ml), potassium carbonate (8.51 g) and DMF (40 ml) were charged to a flask and stirred for 2 h. The residue was partitioned between ether and water, the organics were separated then dried (MgSO_4) and evaporated under reduced pressure. The residue was dissolved in DCM (100 ml), cooled to 0 °C, MCPBA (26.5 g) was added. The reaction mixture was stirred overnight then diluted with DCM, washed with aq sodium metabisulfite, sodium hydrogen carbonate then dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 1:1 isohexane/ ether) to give the subtitle compound (9.5 g).


^1H NMR CDCl_3 -d6: δ 7.99 (1H, d), 7.79-7.84 (1H, m), 7.37-7.31 (1H, m), 3.12 (2H, q), 1.33-1.26 (3H, t).

(ii) {4-chloro-3-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

^1H NMR $\text{DMSO}-d_6$: δ 8.1 (1H, s), 7.81 (1H, dd), 7.6 (1H, d), 7.28-7.25 (2H, m), 6.95-6.92 (1H, d), 3.62 (2H, s), 3.42-3.32 (2H, q), 1.47-1.07 (3H, t).

MS: ESI-ve 386 (M-H) .

Example 4**{4-chloro-3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid****(i) ethyl 4-fluoro-3-(trifluoromethyl)phenyl sulfide**

5 The subtitle compound was prepared by the method of example 2 steps (i) and (ii).


¹H NMR CDCl₃-d₆: δ 7.51 (2H, dd), 7.13 (1H, t), 2.95 (2H, q), 1.28 (3H, t).

(ii) {4-chloro-3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid

10 The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 8.19 (1H, s), 8.11 (1H, d), 7.6 (1H, d), 7.29 (2H, m), 6.97-6.95 (1H, d), 3.52 (2H, s), 3.43-3.36 (2H, q), 1.15-1.05 (3H, t).


MS: ESI-ve 421 (M-H).

Example 5**{4-chloro-3-[4-(methylsulfonyl)phenoxy]phenyl}acetic acid**

The title compound was prepared by the method of example 2 step (iii) using the product of example 1 step (iii) and 4-fluorophenyl methyl sulfone.

20 ¹H NMR DMSO-d₆: δ 7.93-7.89 (2H, m), 7.59-7.54 (1H, m), 7.23-7.06 (4H, m), 3.52 (2H, s), 3.18 (3H, s).

MS: APCI-ve 339 (M-H).

Example 6**2-[4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl]propanoic acid**

5

(i) methyl (4-chloro-3-methoxyphenyl)acetate

The product of example 1 step (iii) (1 g), dimethyl sulfate (1 ml), potassium carbonate (1.48 g) and acetone (20 ml) were charged to a flask and heated at reflux for 16 h. The reaction was diluted with water, extracted with EtOAc, dried (MgSO₄) and evaporated under reduced pressure to give the subtitle compound (1.5 g).

¹H NMR CDCl₃-d₆: δ 7.31-7.26 (1H, m), 6.86-6.79 (2H, m), 3.9 (3H, s), 3.73 (3H, s), 3.59 (2H, s).

(ii) methyl 2-(4-chloro-3-methoxyphenyl)propanoate

The product of step (i) (0.5 g) was added to a solution of nBuLi (1.75 ml, 1.6 M in THF) and diisopropylamine (0.4 ml) in THF (10 ml) at -78 °C and stirred for 1 h, then methyl iodide (0.18 ml) was added, stirred for 1 h at -78 °C then at room temperature for 1h and quenched with water. The product was extracted with ether, dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 1:1 isohexane/ ether) to give the subtitle compound (0.21 g).

¹H NMR CDCl₃-d₆: δ 7.3-7.26 (1H, m), 6.87-6.81 (2H, m), 3.9 (3H, s), 3.67 (3H, s), 3.48 (1H, q), 1.47 (3H, d).

(iii) methyl 2-(4-chloro-3-hydroxyphenyl)propanoate

48% aqueous HBr (10 ml) was added to the product of step (ii) (0.21 g) in acetic acid (10 ml) and heated at 100 °C for 10 h.

MS: ESI-ve 199 (M-H).

(iv) **2-{[4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl]propanoic acid**


The title compound was prepared by the method of example 2 step (iii) using the product of step (iii) and 3-chloro-4-fluorophenyl methyl sulfone.

¹H NMR DMSO-d₆: δ 8.14 (1H, s), 7.82 (1H, d), 7.61 (1H, d), 7.27 (2H, m), 6.88 (1H, d),
3.71 (1H, q), 3.26 (3H, s), 1.34 (3H, d).

MS: APCI-ve 387 (M-H).

Example 7

(4-chloro-3-[2-chloro-4-[(dimethylamino)sulfonyl]phenoxy]phenyl)acetic acid




The title compound was prepared by the method of example 2 step (iii) using 3-chloro-4-fluoro-*N,N*-dimethylbenzenesulfonamide and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 7.93 (1H, s), 7.7 (2H, m), 7.24 (2H, m), 6.93 (1H, d), 3.61 (2H, s),
2.64 (6H, s).

MS: APCI-ve 401(M-H).

Example 8

[4-chloro-3-(3-cyanophenoxy)phenyl]acetic acid



The product from example 1 step (iii) (0.5 g), 3-bromobenzonitrile (0.73 g), cesium carbonate (2.61 g), copper(I)chloride (0.13 g), 2,2,6,6-tetramethyl-3,5-heptanedione (0.06 ml) and NMP (10 ml) were charged to a flask and heated at 120 °C for 16 h. The mixture was partitioned between ether and 2M NaOH, the aqueous layer was acidified then

extracted with EtOAc, dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by RPHPLC to give the title compound (0.015 g).


¹H NMR DMSO-d₆: δ 7.57-7.42 (4H, m), 7.28-7.12 (3H, m), 3.46 (2H, s).

MS: APCI-ve 286 (M-H).

5

Example 9

{4-chloro-3-[2-fluoro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid



The title compound was prepared by the method of example 2 step (iii) using 3,4-difluorophenyl methyl sulfone and the product of example 1 step (iii).

10


¹H NMR DMSO-d₆: δ 7.98 (1H, d), 7.7 (1H, d), 7.54 (1H, d), 7.2 (2H, m), 7.01 (1H, t), 7.06 (1H, s), 3.27 (3H, s), 3.48 (2H, s).

MS: APCI-ve 357 (M-H).

15

Example 10

{4-chloro-3-[4-(ethylsulfonyl)-2-fluorophenoxy]phenyl}acetic acid



(i) 3,4-difluorophenyl ethyl sulfide

A solution of 3,4-difluorothiophenol (3 g), ethyl iodide (1.6 ml), potassium carbonate (2.64 g) and DMF (40 ml) were charged to a flask and stirred for 2 h. The solution was partitioned between ethyl acetate and water. The organic extracts were dried (MgSO₄) and evaporated under reduced pressure to give the subtitle compound (3.84 g).

20

¹H NMR CDCl₃-d₆: δ 7.19-7.032 (3H, m), 2.95 (2H, q), 1.29 (3H, t).

25

(ii) 3,4-difluorophenyl ethyl sulfone

The subtitle compound was prepared by the method of example 2 step (ii) using the product of step (i).


¹H NMR CDCl₃-d₆: δ 7.75 (2H, m), 7.4 (1H, q), 3.15 (2H, q), 1.33 (3H, t).

(iii) {4-chloro-3-[4-(ethylsulfonyl)-2-fluorophenoxy]phenyl}acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (ii) and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 7.93 (1H, d), 7.6 (2H, m), 7.23-7.21 (2H, m), 7.04 (1H, t), 3.55 (2H, s), 3.35 (2H, q), 1.1 (3H, t).

MS: APCI-ve 371 (M-H).

Example 11**{4-chloro-3-[2-cyano-4-(methylsulfonyl)phenoxy]phenyl}acetic acid****(i) 2-chloro-5-(methylsulfonyl)benzonitrile**

The subtitle compound was prepared by the methods of example 2 steps (i) and (ii) using 5-amino-2-chlorobenzonitrile and dimethyldisulfide.


¹H NMR CDCl₃-d₆: δ 8.26 (1H, s), 8.09 (1H, d), 7.76 (1H, d), 3.1 (3H, s).

(ii) {4-chloro-3-[2-cyano-4-(methylsulfonyl)phenoxy]phenyl}acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 8.48 (1H, s), 8.11 (1H, d), 7.58 (1H, d), 7.37-7.27 (2H, m), 6.9 (1H, d), 3.46 (2H, s), 3.26 (3H, s).

MS: APCI-ve 364 (M-H).

Example 12**{4-chloro-3-[2-cyano-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid**5 (i) **2-chloro-5-(ethylsulfonyl)benzonitrile**

The subtitle compound was prepared by the methods of example 2 steps (i) and (ii) using 5-amino-2-chlorobenzonitrile and diethyldisulfide.


^1H NMR CDCl_3 -d6: δ 8.21 (1H, s), 8.05 (1H, d), 7.75 (1H, d), 3.6 (2H, q), 1.32 (3H, t).

10 (ii) **{4-chloro-3-[2-cyano-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid**

The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

^1H NMR $\text{DMSO}-d_6$: δ 8.43 (1H, s), 8.07 (1H, d), 7.59 (1H, d), 7.39-7.21 (2H, m), 6.9 (1H, d), 3.49 (2H, s), 3.35 (2H, q), 1.09 (3H, t).

15 MS: APCI-ve 378 (M-H).

Example 13**{4-chloro-3-[4-(methylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid**20 (i) **4-fluoro-3-(trifluoromethyl)phenylmethyl sulfone**

The subtitle compound was prepared by the methods of example 2 steps (i) and (ii) using 4-fluoro-3-(trifluoromethyl)aniline and dimethyldisulfide.


^1H NMR CDCl_3 -d6: δ 8.22 (2H, d), 7.44 (1H, t), 3.1 (3H, s).

(ii) {4-chloro-3-[4-(methylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 8.19 (1H, d), 7.56-7.55 (2H, m), 7.28-7.23 (3H, m), 3.43 (2H, s), 3.26 (3H, s).


MS: APCI-ve 407 (M-H).

Example 14**{4-chloro-3-[2-cyano-5-(trifluoromethyl)phenoxy]phenyl}acetic acid**

The title compound was prepared by the method of example 2 step (iii) using 3-fluoro-4-(trifluoromethyl)benzonitrile and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 8.22 (1H, d), 7.7 (2H, d), 7.36-7.27 (2H, m), 7 (1H, s), 3.59 (2H, s).

MS: APCI-ve 354 (M-H).

Example 15**(4-chloro-3-{2-fluoro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid****(i) 3,4-difluorophenyl 4-fluorophenyl sulfone**

The subtitle compound was prepared by the method of example 10 step (i) and example 2 step (ii) using 3,4-difluorobenzenethiol and 1-(bromomethyl)-4-fluorobenzene.


¹H NMR CDCl₃-d₆: δ 7.51-7.46 (1H, m), 7.41-7.37 (1H, m), 7.29-7.23 (1H, m), 7.12-7.00 (4H, m), 4.29 (2H, s).

(ii) (4-chloro-3-{2-fluoro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 7.79 (1H, d), 7.6 (1H, d), 7.48 (1H, d), 7.25-7.14 (6H, m), 7.03-6.98 (1H, t), 4.75 (2H, s), 3.57 (2H, s).


MS: APCI-ve 451 (M-H).

Example 16**[3-(4-benzoyl-2-fluorophenoxy)-4-chlorophenyl]acetic acid**

The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and 3,4-difluorobenzophenone.

¹H NMR DMSO-d₆: δ 7.70-7.75 (1H, d), 7.6-7.57 (1H, d), 7.48-7.44 (1H, d), 7.25-7.14 (6H, m), 7.03-6.98 (1H, t), 4.75 (2H, s), 3.57 (2H, s).

MS: APCI-ve 385 (M-H).

Example 17**(4-chloro-3-{2-chloro-4-[(isobutylamino)carbonyl]phenoxy}phenyl)acetic acid****(i) 3-chloro-4-fluoro-N-isobutylbenzamide**

Isobutyl amine (2 molar equivalent) was added to a solution of 3-chloro-4-fluorobenzoyl chloride (1 g) in DCM (10 ml) and stirred for 2 h. The reaction was diluted with DCM, washed with water, dried (MgSO₄) and evaporated under reduced pressure to give a white solid (1.2 g).

MS: ESI+ve 230 (M+H).

(ii) (4-chloro-3-{2-chloro-4-[(isobutylamino)carbonyl]phenoxy}phenyl)acetic acid


The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

¹H NMR DMSO-d₆: δ 8.53 (1H, t), 8.07 (1H, s), 7.8 (1H, d), 7.57 (1H, d), 7.17 (1H, d), 7.06 (1H, s), 6.88 (1H, d), 3.58 (2H, s), 3.08 (2H, t), 1.82 (1H, q), 0.88 (6H, d).

MS: APCI-ve 396 (M+H).

Example 18

{3-chloro-5-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid



(i) 3-chloro-5-methoxybenzoic acid

Sodium methoxide (25% wt., 7 ml) was added to a stirred solution of 3,5-dichlorobenzoic acid (2 g) in DMPU (10 ml) and heated at 170 °C for 5 days. The reaction was poured onto 1M HCl (50 ml). The resulting solid formed was filtered and washed with water, then dried in vacuo to give the subtitle compound (0.8 g).

¹H NMR DMSO-d₆: δ 13.34 (1H, s), 7.46 (1H, s), 7.38 (1H, s), 7.3 (1H, s), 3.77 (3H, s).

(ii) (3-chloro-5-methoxyphenyl)methanol

Lithium aluminium hydride (1M in THF, 8.76 ml) was added dropwise to a stirred solution of the product of step (i) (1.63 g) in THF (40 ml) and stirred for 2 h. The reaction was diluted with 2 M HCl and extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydrogen carbonate, dried (MgSO₄) and evaporated under reduced pressure to give the subtitle compound (1.53 g).

¹H NMR CDCl₃-d₆: δ 6.93 (1H, s), 6.82-6.71 (2H, m), 4.63 (2H, s), 3.79 (3H, s).

(iii) (3-chloro-5-methoxyphenyl)acetonitrile

Phosphorous tribromide (0.28 ml) was added to a solution of the product of step (ii) (1.55 g) in ether (20 ml) at 0 °C, then stirred for 30 min. The reaction mixture was partitioned between ether and aqueous sodium hydrogen carbonate, the organics were separated then dried (MgSO₄) and evaporated under reduced pressure. The residue was dissolved in DMF (20 ml) and sodium cyanide (0.5 g) was added. The mixture was stirred overnight then partitioned between ether and water; the organics were separated, washed with aqueous sodium hydrogen carbonate then dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 1:1 ether/ isohexane) to give the subtitle compound (0.53g).

¹H NMR CDCl₃-d6: δ 6.91-6.9 (1H, m), 6.86-6.85 (1H, m), 6.77-6.76 (1H, m), 3.79 (3H, s), 3.69 (2H, s).

(iv) (3-chloro-5-hydroxyphenyl)acetic acid

The product of step (iii) (0.53 g), tetrabutylammonium chloride (0.123 g) and 48 % aqueous HBr (10 ml) were charged to a flask and heated at 125 °C for 36 h. The reaction mixture was partitioned between water and ethyl acetate, the organics were separated then dried (MgSO₄) and evaporated under reduced pressure.


¹H NMR DMSO-d6: δ 12.33 (1H, s), 9.87 (1H, s), 6.75-6.65 (3H, m), 3.50 (2H, s).

(v) {3-chloro-5-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (iv) and 3-chloro-4-fluorophenyl methyl sulfone.

¹H NMR DMSO-d6: δ 8.14 (1H, s), 7.87 (1H, d), 7.33-7.02 (4H, m), 3.62 (2H, s), 3.27 (3H, s).


MS: APCI+ve 392 (M+NH₄).

Example 19**{3-chloro-5-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid**

The title compound was prepared by the method of example 2 step (iii) using the product of example 3 step (i) and the product of example 18 step (iv).

¹H NMR DMSO-d₆: δ 8.07 (1H, s), 7.82 (1H, d), 7.2 (3H, m), 7.03 (1H, s), 3.59 (2H, s), 3.35 (2H, q), 1.1 (3H, t).

MS: APCI-ve 386 (M-H).

Example 20**{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-fluorophenyl}acetic acid****(i) 3-fluoro-5-methoxybenzoic acid**

The subtitle compound was prepared by the method of example 18 step (i) using 3,5-difluoro-benzoic acid.

MS: APCI-ve 169 (M-H).

(ii) (3-fluoro-5-methoxyphenyl)methanol

The subtitle compound was prepared by the method of example 18 step (ii) using the product of step (i)

¹H NMR CDCl₃-d₆: δ 6.68 (2H, m), 6.53 (1H, m), 4.67 (2H, d), 3.8 (3H, s).

(iii) (3-fluoro-5-methoxyphenyl)acetonitrile

Thionyl chloride (0.95 ml) was added to a solution of the product of step (ii) (0.95 ml) in DCM (20 ml) at 0 °C, then stirred for 1 h. The reaction mixture was washed with 2M HCl,

the organics were separated then dried (MgSO_4) and evaporated under reduced pressure. The residue was dissolved in DMF (10 ml) and sodium cyanide (0.3 g) was added. The mixture was stirred for 2 h, then partitioned between ether and water; the organics were separated, then dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 1:1 ether/ isohexane) to give the subtitle compound (0.47 g).

^1H NMR CDCl_3 -d6: δ 6.66 (3H, m), 3.81 (3H, s), 3.70 (2H, s).

(iv) (3-fluoro-5-hydroxyphenyl)acetic acid

The subtitle compound was prepared by the method of example 18 step (iv) using the product of step (iii)

^1H NMR DMSO-d6: δ 12.10 (1H, s), 9.79 (1H, s), 6.42 (3H, m), 3.44 (2H, s).

(v) {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-fluorophenyl}acetic acid


The title compound was prepared by the method of example 2 step (iii) using the product of step (iv) and the product of example 3 step (i).

^1H NMR DMSO-d6: δ 8.07 (1H, m), 7.82 (1H, d), 7.22 (1H, d), 7.03-6.89 (3H, m), 3.58 (2H, s), 3.32 (2H, q), 1.12 (3H, t).

MS: APCI-ve 371 (M-H).

Example 21

{3-fluoro-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid




The title compound was prepared by the method of example 2 step (iii) using the product of example 2 step (ii) and the product of example 20 step (iv).

^1H NMR DMSO-d6: δ 8.23 (1H, s), 8.15 (1H, d), 7.23 (1H, d), 7.01 (3H, m), 3.51 (2H, s), 3.3 (3H, s).

MS: APCI-ve 391 (M-H).

Example 22

{3-[2-chloro-4-(ethylsulfonvl)phenoxy]-4-fluorophenyl}acetic acid



(i) 4-fluoro-3-methoxy-benzoic acid

The subtitle compound was prepared by the method of example 1 step (i) using 4-fluoro-3-hydroxybenzoic acid.

MS: APCI-ve 169 (M-H).

(ii) 2-fluoro-5-(hydroxymethyl)phenol

The subtitle compound was prepared by the method of example 18 step (ii) using the product of step (i).

^1H NMR CDCl_3 -d6: δ 7.07-6.98 (2H, m), 6.88-6.80 (1H, m), 4.6 (2H, s), 3.89 (3H, s).

(iii) (4-fluoro-3-hydroxyphenyl)acetonitrile

The subtitle compound was prepared by the method of example 20 step (iii) using the product of step (ii).

^1H NMR CDCl_3 -d6: δ 7.11 (1H, m), 7.03 (1H, m), 6.86 (1H, m), 3.91 (3H, s), 3.72 (2H, s).

(iv) (4-fluoro-3-hydroxyphenyl)acetic acid

The subtitle compound was prepared by the method of example 18 step (iv) using the product of step (iii).


^1H NMR DMSO -d6: δ 7.06-7.0 (2H, m), 6.88-6.83 (1H, m), 4.65-4.63 (2H, d), 3.89 (3H, s).

(v) {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-4-fluorophenyl}acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (iv) and the product of example 3 step (i).

¹H NMR DMSO-d₆: δ 8.07 (1H, s), 7.79 (1H, d), 7.4-7.35 (1H, m), 7.26-7.2 (2H, m), 7.03 (1H, d), 3.50 (2H, s), 3.36 (2H, q), 1.09 (3H, t)


MS: APCI-ve 371 (M-H).

Example 23**{4-fluoro-3-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid**

The title compound was prepared by the method of example 2 step (iii) using the product of example 22 step (iv) and the product of example 2 step (ii).

¹H NMR DMSO-d₆: δ 8.24 (1H, s), 7.39-7.21 (3H, m), 7.10-7.07 (1H, d), 3.3 (3H, s).

MS: APCI-ve 391 (M-H).

Example 24**{4-chloro-3-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid****(i) 3,4-difluorophenyl phenyl sulfone**

3,4-difluoroaniline (3.5 g), acetonitrile (60 ml), diphenyldisulfide (6 g) and isoamyl nitrite (8 ml) were charged to a flask and heated at 60 °C for 2h then evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent isohexane) to give the subtitle compound. The product (3,4-difluorophenyl phenyl sulfide) was

dissolved in acetonitrile (60 ml). Water (10 ml) and oxone (20 g) were added and stirred for 72 h at RT. The reaction mixture was partitioned between ether/water, the organics were separated, washed with water, then dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 5-10 % ethyl acetate/ isohexane) to give the subtitle compound (2.14 g).

^1H NMR CDCl_3 -d6: δ 7.93 (2H, d), 7.81-7.71 (2H, m), 7.64-7.51 (3H, m), 7.34-7.28 (1H, m).

(ii) {4-chloro-3-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid


The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 1 step (iii).

^1H NMR DMSO-d_6 : δ 8.07-7.99 (3H, m), 7.78-7.51 (5H, m), 7.21-7.19 (2H, m), 6.93 (1H, t), 3.43 (2H, s).

MS: APCI-ve 419 (M-H).

Example 25

[3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl]-5-(trifluoromethyl)phenyl]acetic acid



(i) 3-methoxy-5-(trifluoromethyl)benzoic acid

The subtitle compound was prepared by the method of example 1 step (i) using 3-fluoro-5-(trifluoromethyl)benzoic acid.

MS: APCI-ve 219 (M-H).

(ii) [3-methoxy-5-(trifluoromethyl)phenyl]methanol

The subtitle compound was prepared by the method of example 18 step (ii) using the product of step (i).

^1H NMR CDCl_3 -d6: δ 7.26-7.04 (3H, m), 4.72 (2H, s), 4.08 (3H, s).

(iii) [3-methoxy-5-(trifluoromethyl)phenyl]acetonitrile

Triethylamine (2.04 ml) was added to a solution of the product of step (ii) (3.02 g) in DCM (30 ml) and cooled to 0 °C before adding methane sulfonyl chloride (1.13 ml). The reaction mixture was stirred for 2 h at RT. The reaction mixture was diluted with water, extracted with DCM then dried (MgSO₄) and evaporated under reduced pressure to give an oil. The oil was dissolved in DMF (20 ml), sodium cyanide (1.07 g) was added and stirred at 100 °C for 2 h. The reaction mixture was diluted with water, extracted with ether, dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent ether) to give the subtitle compound (1.9 g).

¹H NMR CDCl₃-d₆: δ 7.16-7.06 (3H, m), 3.87 (3H, s), 3.78 (2H, s).

(iv) [3-hydroxy-5-(trifluoromethyl)phenyl]acetic acid

The subtitle compound was prepared by the method of example 18 step (iv) using the product of step (iii).


¹H NMR DMSO-d₆: δ 7.02-6.83 (3H, m), 3.60 (2H, s).

(v) [3-[2-chloro-4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid

The title compound was prepared by the method of example 2 step (iii) using the product of step (iv) and 3-chloro-4-fluorophenyl methyl sulfone.

¹H NMR DMSO-d₆: δ 8.16 (1H, s), 7.89 (1H, d), 7.53 (1H, s), 7.37-7.23 (3H, m), 3.65 (2H, s), 3.29 (3H, s).

MS: APCI-ve 407 (M-H).

Example 26**[3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid**


The title compound was prepared by the method of example 2 step (iii) using the product of example 25 step (iv) and the product of example 3 step (i).

^1H NMR DMSO-d₆: δ 8.09 (1H, s), 7.83 (1H, d), 7.54-7.17 (4H, m), 3.70 (2H, s), 3.37 (2H, q), 1.12 (3H, t).

MS: APCI-ve 421 (M-H).

5 **Example 27**

{3-chloro-5-[2-fluoro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid




The title compound was prepared by the method of example 2 step (iii) using 3,4-difluorophenyl methyl sulfone and the product of example 18 step (iv).

10 ^1H NMR DMSO-d₆: δ 7.81 (1H, dd), 7.71 (1H, d), 7.15 (2H, s), 6.96 (1H, d), 6.89 (1H, s), 3.61 (2H, s), 3.09 (3H, s).

MS: APCI-ve 343 (M-CH₃).

Example 28


15 **{3-chloro-5-[2-cyano-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid**



The title compound was prepared by the method of example 2 step (iii) using the product of example 12 step (ii) and the product of example 18 step (iv).

20 ^1H NMR DMSO-d₆: δ 8.41 (1H, d), 8.08 (1H, dd), 7.40 (1H, dd), 7.37 (1H, dd), 7.21 (1H, d), 7.13 (1H, d), 3.66 (2H, s), 3.37 (2H, q) and 1.12 (3H, t).

MS: APCI-ve 334 (M-CO₂).

Example 29**{3-chloro-5-[2-chloro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid****(i) 3-chloro-4-fluorophenyl phenyl sulfone**

- 5 Ferric chloride (0.47 g), was added to a stirred mixture of 3-chloro-4-fluorosulfonyl chloride (1.5 g) and benzene (10 ml). The reaction mixture was then heated to reflux for 18 h, then allowed to cool to room temperature. The solvent was evaporated in vacuo and the residue was partitioned between DCM and aqueous sodium hydrogen carbonate, then extracted with DCM (x 2). The combined organic extracts were washed with brine, dried
- 10 (MgSO₄) and evaporated under reduced pressure. The residual solid was recrystallised from ethanol to give the subtitle compound as buff coloured crystals (1.1 g).

¹H NMR CDCl₃: δ 8.02-7.31 (8H, m).


(ii) {3-chloro-5-[2-chloro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid

- 15 The title compound was prepared by the method of example 2 step (iii) using the product of step (i) and the product of example 18 step (iv).

¹H NMR DMSO-d₆: δ 8.19 (1H, d), 8.02 (2H, d), 7.91 (1H, dd), 7.76-7.63 (3H, m), 7.28 (1H, s), 7.18-7.13 (2H, m), 7.03 (1H, s), 3.56 (2H, s).

MS: APCI-ve 391 (M-CO₂).

20


Example 30**{3-chloro-5-[4-(ethylsulfonyl)-2-fluorophenoxy]phenyl}acetic acid**

- The title compound was prepared by the method of example 2 step (iii) using the product of example 10 step (ii) and the product of example 18 step (iv).
- 25

^1H NMR DMSO- d_6 : δ 7.77 (1H, dd), 7.67 (1H, dd), 7.21-7.12 (2H, m), 6.98 (1H, d), 6.89 (1H, s), 3.62 (2H, s), 3.15 (2H, q), 1.32 (3H, t).
MS: APCI-ve 327 (M- CO_2).

5 **Example 31**

[3-chloro-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl]acetic acid




The title compound was prepared by the method of example 2 step (iii) using the product of example 24 step (i) and the product of example 18 step (iv).

10 ^1H NMR DMSO- d_6 : δ 7.96-7.93 (2H, dd), 7.76-7.62 (2H, m), 7.61-7.48 (3H, m), 7.06-7.03 (2H, m), 6.88 (2H, d), 3.55 (2H, s).
MS: APCI-ve 419 (M-H).


Example 32

15 **[3-(2-fluoro-4-[(4-fluorobenzyl)sulfonyl]phenoxy]-5-(trifluoromethyl)phenyl]acetic acid**



The title compound was prepared by the method of example 2 step (iii) using the product of example 25 step (iv) and the product of example 15 step (i).


20 ^1H NMR DMSO- d_6 : δ 7.76-7.80 (1H, d) 7.48-7.53 (2H, m), 7.12-7.34 (7H, m), 4.76 (2H, s), 3.74 (2H, s).
MS: APCI-ve 441 (M- CO_2).

Example 33**(3-chloro-5-{4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from example 15 step (i).

¹H NMR DMSO-d₆: δ 7.77-7.74 (1H, d), 7.53-7.47 (1H, d), 7.41-7.11 (8H, m), 4.76 (2H, s), 3.61 (2H, s).

MS: ESI-ve 407 (M-CO₂).

Example 34**(3-chloro-5-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid****(i) 2-chloro-1-fluoro-4-[(4-fluorobenzyl)sulfonyl]benzene**

A solution of 3-chloro-4-fluorobenzenethiol (1.0 g), 1-(bromomethyl)-4-fluorobenzene (1.15 g) and potassium carbonate (0.85 g) in DMF (10 ml) was stirred overnight at RT then diluted with water, extracted with ether, and the organics dried (MgSO₄) and evaporated under reduced pressure. The resulting oil was dissolved in DCM (10 ml) and MCPBA (1.2 g) added and stirred at RT overnight. The solution was then washed with aqueous sodium metabisulphite and aqueous sodium hydrogen carbonate, dried (MgSO₄) and evaporated under reduced pressure to give an oil which was purified by flash column chromatography (eluting 3:2 i-hexane / ether) to give the subtitle compound as a white solid (1.3 g).

¹H NMR CDCl₃: δ 7.74-7.71 (1H, d), 7.53-7.49 (1H, m), 7.28-7.20 (2H, m), 7.08-7.06 (1H, m), 6.92-6.86 (2H, m), 4.31 (2H, s).

(ii) (3-chloro-5-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid


The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.89-7.87 (1H, s), 7.64-7.59 (1H, d), 7.33-7.00 (8H, m), 4.76 (2H, s), 3.62 (2H, s).

MS: ESI-ve 423 (M-CO₂).

Example 35

{3-chloro-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid




The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from example 2 step (ii).

¹H NMR DMSO-d₆: δ 8.24-8.15 (2H, m), 7.27-7.16 (3H, m), 7.05 (1H, s), 3.46 (2H, s), 3.30 (3H, s).

MS: ESI-ve 363 (M-CO₂).

Example 36

{3-chloro-5-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid




The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from example 4 step (i).

¹H NMR DMSO-d₆: δ 8.24-8.15 (2H, m), 7.27-7.16 (3H, m), 7.05 (1H, s), 3.54 (2H, s), 3.46 (2H, q), 1.15-1.06 (3H, t).

MS: ESI-ve 377 (M-CO₂).

Example 37

[3-[2-fluoro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid




The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from example 24 step (i).

¹H NMR DMSO-d₆: δ 8.11-8.01 (3H, m), 7.82-7.63 (4H, m), 7.54 (1H, s) 7.45 (1H, s) 7.32 (1H, s), 7.28-7.24 (1H, t), 3.74 (2H, s).

MS: ESI-ve 409 (M-CO₂).

Example 38


[3-[2-chloro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid



The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from example 29 step (i).

¹H NMR DMSO-d₆: δ 8.17 (1H, s), 8.01-7.99 (2H, d), 7.91-7.88 (1H, d), 7.72-7.61 (3H, m) 7.50 (1H, s) 7.37-7.31 (2H, d), 7.12-7.09 (1H, d), 3.57 (2H, s).


MS: ESI-ve 425 (M-CO₂).

Example 39**[3-[4-(ethylsulfonyl)-2-fluorophenoxy]-5-(trifluoromethyl)phenyl]acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from example 10 step (ii).

¹H NMR DMSO-d₆: δ 7.96-7.92 (1H, d), 7.73-7.71 (1H, d), 7.50 (1H, s), 7.37-7.30 (3H, m), 3.58 (2H, s), 3.38-3.33 (2H, q), 1.17-1.11 (3H, t).


MS: ESI-ve 361 (M-CO₂).

Example 40**[3-[2-cyano-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from example 12 step (i).

¹H NMR DMSO-d₆: δ 8.46-8.45 (1H, m), 8.13-8.09 (1H, d), 7.65 (2H, bm), 7.54 (1H, s), 7.15-7.12 (1H, d), 3.69 (2H, s), 3.43-3.35 (2H, q), 1.16-1.11 (3H, t).


MS: ESI-ve 368 (M-CO₂).

Example 41**{3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-(trifluoromethyl)phenyl}acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from example 4 step (i).

¹H NMR DMSO-d₆: δ 8.21-8.14 (2H, m), 7.62 (1H, s), 7.52 (1H, s), 7.46 (1H, s), 7.26-7.24 (1H, d), 3.73 (2H, s), 3.46-3.39 (2H, q), 1.17-1.11 (3H, t).

MS: ESI-ve 411 (M-CO₂).

Example 42**{3-[4-(benzylsulfonyl)-2-chlorophenoxy]-5-chlorophenyl}acetic acid****(i) 4-(benzylsulfonyl)-2-chloro-1-fluorobenzene**

The subtitle compound was prepared by the method of example 34 step (i) using 3-chloro-4-fluorobenzenethiol (1.0 g) and benzyl bromide (0.73 ml) to give a white solid (1.2 g).


¹H NMR CDCl₃: δ 7.68-7.65 (1H, d), 7.49-7.09 (7H, m), 4.31 (2H, s).

(ii) {3-[4-(benzylsulfonyl)-2-chlorophenoxy]-5-chlorophenyl}acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.88-7.87 (1H, s), 7.65-7.61 (1H, d), 7.35-7.19 (7H, m), 7.08-6.99 (2H, m), 4.76 (2H, s), 3.60 (2H, s).

MS: APCI-ve 449 (M-H).

Example 43**{3-chloro-5-[4-(phenylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid****(i) 1-fluoro-4-(phenylsulfonyl)-2-(trifluoromethyl)benzene**

- 5 4-Fluoro-3-(trifluoromethyl)aniline (5.0 g), diphenyldisulfide (6.0 g) and isoamylnitrite (8 ml) in acetonitrile (60 ml) were heated at 60 °C for 2 h, then cooled and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent isohexane) then dissolved in acetonitrile (60 ml) and water (10 ml) then oxone (20 g) added and the mixture stirred at RT for 72 h. The mixture was extracted between ether and
- 10 water and the organics dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent: 5 to 10 % ethyl acetate in isohexane) to give the subtitle compound (2.14 g).


¹H NMR DMSO-d₆: δ 8.24-8.13 (2H, m), 7.95 (2H, d), 7.66-7.53 (3H, m), 7.32 (1H, t).

15 **(ii) {3-chloro-5-[4-(phenylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 8.25-8.20 (2H, m), 8.06-8.03 (2H, d), 7.76-7.63 (3H, m), 7.38-7.10 (4H, m), 3.56 (2H, s).

- 20 MS: APCI-ve 469 (M-H).

Example 44**{3-chloro-5-[2-cyano-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid**

(i) 2-chloro-5-(phenylsulfonyl)benzonitrile

A solution of 5-amino-2-chlorobenzonitrile (6.6 g), diphenyldisulphide (11.0 g) and isoamyl nitrile (10 ml) in acetonitrile (100 ml) was heated at 60 °C for 6 h then evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent: iso-hexane to 1% EtOAc in iso-hexane) and the resulting solid dissolved in DCM. MCPBA (8.0 g) was added portionwise and the mixture stirred for 2 h, filtered and the filtrate washed with aqueous sodium metabisulphite, aqueous sodium hydrogen carbonate then water and the organics dried (MgSO₄) and evaporated under reduced pressure to give the subtitle compound (2.9 g).


¹H NMR CDCl₃: δ 8.22 (1H, s), 8.08 (1H, d), 7.95 (2H, d), 7.68-7.54 (4H, m).

(ii) {3-chloro-5-[2-cyano-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 8.59 (1H, s), 8.19-8.15 (1H, d), 8.04-8.01 (2H, d), 7.76-7.63 (3H, m), 7.30-7.29 (2H, m), 7.13 (1H, s), 7.06-7.03 (1H, d), 3.41 (2H, s).

MS: APCI-ve 426 (M-H).

Example 45**{3-[4-(benzylsulfonyl)-2-fluorophenoxy]-5-chlorophenyl}acetic acid****(i) 4-(benzylsulfonyl)-1,2-difluorobenzene**

The subtitle compound was prepared by the method of example 34 step (i) using 3,4-difluorobenzenethiol (1.3 g) and benzyl bromide (1.5 ml) to give a white solid (2.4 g).


¹H NMR CDCl₃: δ 7.48-7.20 (8H, m), 4.33 (2H, s).

(ii) {3-[4-(benzylsulfonyl)-2-fluorophenoxy]-5-chlorophenyl}acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 and the product from step (i).

¹H NMR DMSO-d₆: δ 7.77-7.73 (1H, d), 7.66-7.51 (1H, d), 7.35-7.18 (7H, m), 7.05-6.99 (2H, m), 4.75 (2H, s), 3.61 (2H, s).

MS: APCI-ve 433 (M-H).

Example 46**(3-chloro-5-{2-fluoro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid****(i) 1,2-difluoro-4-[(3-fluorophenyl)sulfonyl]benzene**

The subtitle compound was prepared by the method of example 34 step (i) using 3,4-difluorobenzenethiol (1.0 g), and 1-(bromomethyl)-3-fluorobenzene (1.28 g) to give a white solid (1.4g).


¹H NMR CDCl₃: δ 7.53-7.39 (2H, m), 7.32-7.22 (2H, m), 7.09-7.03 (1H, m), 6.90-6.86 (2H, m), 4.30 (2H, s).

(ii) (3-chloro-5-{2-fluoro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.78-7.74 (1H, d), 7.52-7.49 (1H, d), 7.41-7.15 (4H, m), 7.06-6.96 (4H, m), 4.79 (2H, s), 3.48 (2H, s).

MS: APCI-ve 407 (M-CO₂).


Example 47**{3-[4-(benzylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-chlorophenyl}acetic acid****(i) 4-(benzylsulfonyl)-1-fluoro-2-(trifluoromethyl)benzene**

- 5 The subtitle compound was prepared by the method of example 44 step (i) using 3-trifluoromethyl-4-fluoroaniline (2.0 g) and dibenzyldisulfide to give a white solid (0.42 g).
¹H NMR CDCl₃: δ 7.80-7.77 (2H, m), 7.39-7.25 (4H, m), 7.10-7.07 (2H, d), 4.34 (2H, s).

(ii) {3-[4-(benzylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-chlorophenyl}acetic acid

- 10 The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).
¹H NMR DMSO-d₆: δ 7.94-7.86 (2H, d), 7.33-7.28 (4H, m), 7.20-7.16 (4H, m), 7.05 (1H, s), 4.76 (2H, s), 3.54 (2H, s).
 MS: APCI-ve 439 (M-CO₂).

15

Example 48**(3-chloro-5-{2-fluoro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid****(i) 1,2-difluoro-4-[(2-fluorobenzyl)sulfonyl]benzene**


- 20 The subtitle compound was prepared by the method of example 34 step (i) using 3,4-difluorobenzenethiol (1.0 g), and 1-(bromomethyl)-2-fluorobenzene (1.28 g) to give a white solid (2.3g).
¹H NMR CDCl₃: δ 7.62-7.14 (6H, m), 6.97-6.90 (1H, t), 4.41 (2H, s).

(ii) (3-chloro-5-{2-fluoro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.81-7.75 (1H, d), 7.57-7.39 (2H, d), 7.33-7.16 (5H, m), 7.06-6.97 (2H, m), 4.78 (2H, s), 3.49 (2H, s).

MS: APCI-ve 407 (M-CO₂).

Example 49**(3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid****(i) 4-[(4-chlorobenzyl)sulfonyl]-1,2-difluorobenzene**

Ferric chloride (1.27 g), was added to a stirred mixture of 3,4-difluorosulfonyl chloride (5 g) and chlorobenzene (4.65 ml). The reaction mixture was heated to reflux for 16 h then allowed to cool to room temperature. The reaction mixture was diluted with water, extracted with ethyl acetate (x 2). The combined organic extracts were washed with brine, dried (MgSO₄) and evaporated under reduced pressure. The residual solid was recrystallised from ethanol to give the subtitle compound as buff coloured crystals (4.35g).


¹H NMR CDCl₃: δ 7.53-7.48 (2H, m), 7.30-7.22 (3H, m), 7.07-7.04 (2H, d), 4.28 (2H, s).

(ii) (3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 12.49 (1H, s), 7.80-7.77 (1H, d), 7.51-7.19 (7H, m), 7.11 (1H, s), 7.02 (1H, s), 4.77 (2H, s), 3.64 (2H, s).

MS: APCI-ve 409 (M-CO₂).

Example 50**2-[3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid****5 (i) methyl [3-methoxy-5-(trifluoromethyl)phenyl]acetate**

The product from example 25 step (iv) (1.0 g) was dissolved in dry DMF (10 ml) and treated with iodomethane (0.6 ml) and potassium carbonate (1.25 g). The mixture was stirred at room temperature overnight. The mixture was diluted with water, extracted with ether, dried (MgSO₄) and evaporated under reduced pressure to give an oil. The oil was
 10 purified by flash column chromatography (eluent 2:1 diethylether / isohexane) (1.30 g).
 1H NMR DMSO-d₆ δ 7.13 (1H, s), 7.04-7.01 (2H, d), 3.85 (3H, s), 3.70 (3H, s), 3.65 (2H, s).

(ii) methyl 2-[3-methoxy-5-(trifluoromethyl)phenyl]propanoate

15 The product from step (i) (1.3 g) was added to a pre-formed solution of butyllithium (2.5M in hexanes, 2.51 ml), diisopropylamine (0.88 ml) in dry THF (30 ml) at -78 °C. The mixture was kept at -78 °C for 1 hour before adding iodomethane (0.4 ml). The mixture was slowly allowed to warm to room temperature overnight. The mixture was diluted with 2M HCl, extracted with ether, dried (MgSO₄) and evaporated under reduced pressure to
 20 give an oil. The oil was purified by flash column chromatography (eluent 2:1 isohexane / diethylether) (0.8 g).
 1H NMR DMSO-d₆: δ 7.17-7.13 (1H, s), 7.02 (2H, s), 3.84 (3H, s), 3.74 (1H, q), 3.68 (3H, s), 1.52-1.50 (3H, d).

25 (iii) 2-[3-hydroxy-5-(trifluoromethyl)phenyl]propanoic acid

The product from step (ii) (0.8 g) was dissolved in glacial acetic acid (20 ml) and treated with 48% aqueous HBr (20 ml). The mixture was heated at 100 °C for 16 h. The mixture was cooled and diluted with 2M NaOH, extracted with ethyl acetate, dried (MgSO₄) and

evaporated under reduced pressure to give an oil, which was purified by RPHPLC to give a colourless oil (0.5g).

MS: APCI-ve 233 (M-H).

5 (iv) **2-[3-[4-(ethylsulfonyl)phenoxy]-2-(trifluoromethyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid**


The title compound was prepared as described in example 2 step (iii) but instead using the product from step (iii) and the product from example 4 step (i).

1H NMR DMSO-d₆: δ 8.20-8.19 (1H, s), 8.14-8.11 (1H, d), 7.60 (1H, s), 7.50-7.47 (2H, d), 7.26-7.21 (1H, d), 3.85-3.80 (1H, q), 3.43-3.38 (2H, q), 1.39-1.38 (3H, d), 1.15-1.11 (3H, t).

MS: ESI-ve 425 (M-CO₂).

Example 51


15 **2-[3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid**



The title compound was prepared as described in example 2 step (iii) but instead using the product from example 50 step (iii) and the product from example 3 step (i).


1H NMR DMSO-d₆: δ 8.10-8.09 (1H, s), 7.84-7.82 (1H, d), 7.54 (1H, s), 7.39-7.38 (2H, d), 7.22-7.20 (1H, d), 3.80-3.74 (1H, q), 3.40-3.35 (2H, q), 1.37-1.35 (3H, d), 1.14-1.11 (3H, t).

MS: ESI-ve 391 (M-CO₂).

Example 52**2-[3-(2-chloro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid**


The title compound was prepared as described in example 2 step (iii) but instead using the product from example 50 step (iii) and the product from example 29 step (i).

¹H NMR DMSO-d₆: δ 8.19 (1H, s), 8.02-8.00 (2H, d), 7.91-7.88 (1H, d), 7.73-7.62 (3H, m), 7.53 (1H, s), 7.39-7.37 (2H, d), 7.12-7.09 (1H, d), 3.73-3.71 (1H, q), 1.34-1.32 (3H, d). MS: ESI(-ve) 439 (M-CO₂).

Example 53**2-[3-(2-chloro-4-(4-fluorobenzyl)sulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 50 step (iii) and the product from example 34 step (i).

¹H NMR DMSO-d₆: δ 7.92-7.91 (1H, s), 7.60-7.53 (2H, m), 7.34 (2H, s), 7.25-7.14 (5H, m), 4.77 (2H, s), 3.90-3.84 (1H, q), 1.40-1.39 (3H, d). MS: ESI(-ve) 471 (M-CO₂).

Example 54**(3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid****(i) 4-[(4-chlorobenzyl)sulfonyl]-1,2-difluorobenzene**

- 5 A solution of 3,4-difluorobenzenethiol (1.0 g), 1-(bromomethyl)-4-chlorobenzene (1.28 g) and potassium carbonate (0.94 g) in DMF (10 ml) was stirred overnight at RT then diluted with water, extracted with ether, and the organics dried (MgSO₄) and evaporated under reduced pressure. The resulting oil was dissolved in DCM (10 ml) and MCPBA (2.94 g) added and stirred at RT overnight. The solution was then washed with aqueous sodium
- 10 metabisulphite and aqueous sodium hydrogen carbonate, dried (MgSO₄) and evaporated under reduced pressure to give a solid, triturated with isohexane to give the subtitle compound as a white solid (2.3g).


¹H NMR CDCl₃: δ 7.53-7.48 (2H, m), 7.30-7.22 (3H, m), 7.07-7.04 (2H, d), 4.28 (2H, s).

15 (ii) (3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 12.49 (1H, s), 7.80-7.77 (1H, d), 7.51-7.19 (7H, m), 7.11 (1H, s), 7.02 (1H, s), 4.77 (2H, s), 3.64 (2H, s).

- 20 MS: APCI-ve: 423 (M-CO₂).

Example 55**{3-bromo-5-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid**

(i) 3-bromo-5-methoxybenzonitrile

Sodium methoxide (2.02 g) was added to a stirred solution of 3-fluoro-5-bromobenzonitrile (5.0 g) in DMPU (20 ml) and stirred at RT for 2 h. The reaction was diluted with water and the resulting solid formed was filtered and washed with water, then dried in vacuo to give the subtitle compound (5.10 g).

¹H NMR DMSO-d₆: δ 7.39-7.38 (1H, s), 7.30-7.26 (1H, m), 7.11 (1H, s), 3.83 (3H, s).

(ii) 3-bromo-5-methoxybenzoic acid

The product from step (i) (5.10g) was dissolved in methanol (20 ml) and 6N NaOH (20 ml) and heated to reflux for 6 h. The mixture was diluted with 2M HCl, extracted with ethyl acetate, dried (MgSO₄) and evaporated under reduced pressure to give a white solid (5.10g).

MS: APCI-ve 229 (M-H).

(iii) (3-bromo-5-methoxyphenyl)methanol

Lithium aluminium hydride (1M in THF, 22.07 ml) was added dropwise to a stirred solution of the product of step (ii) (5.1g) in THF (50 ml) at 0 °C and stirred at RT overnight. The reaction was quenched in 2M HCl, extracted with ether, dried (MgSO₄) and evaporated under reduced pressure to give an oil, which was purified by flash column chromatography (eluent 1:1 isohexane/diethylether) to give the subtitle compound (5.38 g).

¹H NMR CDCl₃: δ 7.08 (1H, s), 6.96-6.91 (1H, s), 6.83-6.81 (1H, s), 4.62 (2H, s), 3.79 (3H, s).

(iv) (3-bromo-5-methoxyphenyl)acetonitrile

The product from step (iii) (5.38g) was dissolved in dry DCM (50 ml) and dry DMF (2.3 ml) added followed by thionyl chloride (2.17 ml). The reaction mixture was stirred at RT overnight, and then diluted with aqueous sodium hydrogen carbonate, extracted with DCM, dried (MgSO₄) and evaporated under reduced pressure to give an oil. The oil was dissolved in DMF (20 ml), sodium cyanide (1.30 g) was added and stirred at RT overnight. The reaction mixture was diluted with water, extracted with ether, dried (MgSO₄) and

evaporated under reduced pressure. The residue was purified by flash column chromatography (eluent 1:2 ether / isohexane) to give the subtitle compound (4.50 g).
1H NMR CDCl₃: δ 7.07-7.02 (2H, m), 6.81 (1H, s), 3.83 (3H, s), 3.70 (2H, s).

5 (v) **(3-bromo-5-hydroxyphenyl)acetic acid**

The product of step (iv) (4.5 g), in glacial acetic acid (30 ml) was treated with 48 % aqueous HBr (30 ml) and heated at 100 °C for 24 h. The reaction mixture was partitioned between water and ethyl acetate, the organics were separated then dried (MgSO₄) and evaporated under reduced pressure to give a tan solid which was triturated with ether/isohexane (4.24 g).

MS: APCI-ve 229/231 (M-H).

(vi) **{3-bromo-5-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid**


The title compound was prepared as described in example 2 step (iii) but instead using the product from step (v) and the product from example 3 step (i).

1H NMR DMSO-d₆: 8.08-8.07 (1H, s), 7.84-7.81 (1H, d), 7.38-7.20 (3H, m), 7.07 (1H, s), 3.59 (2H, s), 3.39-3.34 (2H, q), 1.14-1.07 (3H, t).

MS: APCI-ve 431/433 (M-H).

20 **Example 56**

{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methylphenyl}acetic acid



(i) **methyl 3-bromo-5-hydroxybenzoate**

The product from example 55 step (v) (3.24 g) was added to a preformed solution of methanol (200 ml) and acetyl chloride (20 ml) and stirred at RT overnight. The mixture was evaporated under reduced pressure to give an oil. The oil was purified by flash column chromatography (eluent 1:1 ether / isohexane) to give the subtitle compound (3.16 g).

¹H NMR CDCl₃: δ 6.98-6.97 (1H, s), 6.92-6.91 (1H, s), 6.70-6.69 (1H, m), 5.71 (1H, bs), 3.71-3.70 (3H, s), 3.50 (2H, s).

(ii) methyl 3-bromo-5-[2-chloro-4-(ethylsulfonyl)phenoxy]benzoate

- 5 The subtitle compound was prepared as described in example 2 step (iii) but instead using the product from step (i) and the product from example 3 step (i).

MS: APCI-ve 446 (M-II).

(iii) {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methylphenyl}acetic acid


- 10 The title compound was prepared by treating the product from step (ii) (0.6 g) in dry THF (10 ml) with bis(diphenylphosphino)ferrocene palladium (0.1 g) and 2.0M methyl zinc chloride (2.01 ml). The mixture was heated to reflux for 2 h, partitioned between water and ethyl acetate, the organics separated then dried (MgSO₄) and evaporated under reduced pressure to an oil. The oil was purified by flash column chromatography (eluent ether) then
- 15 The mixture was dissolved in methanol (10 ml) and 2M NaOH (10 ml) added and stirred at RT overnight. The mixture was diluted with water, extracted with ether (which was discarded) and the aqueous layer acidified with 2M HCl, extracted with ethyl acetate, and the ethyl acetate layer dried (MgSO₄) and evaporated under reduced pressure to an oil. The oil was purified by RPHPLC to give the title compound.

- 20 ¹H NMR DMSO-d₆: δ 8.04 (1H, s), 7.80-7.78 (1H, d), 7.08-6.77 (4H, m), 3.43 (2H, s), 3.37-3.31 (2H, q), 2.29 (3H, s), 1.13-1.10 (3H, t).

MS: APCI-ve 367 (M-H).

Example 57

- 25 **methyl 3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-cyanobenzoate**




The title compound was prepared using the method described in example 56 step (iii) but instead using the product from example 56 step (ii) and zinc cyanide.

¹H NMR DMSO-d₆: 8.05 (1H, s), 7.84-7.82 (1H, d), 7.64-7.07 (3H, s), 6.99-6.97 (1H, d), 3.49 (2H, s), 3.38-3.34 (2H, q), 1.15-1.11 (3H, t).

MS: APCI-ve 334 (M-H).

5 **Example 58**

[3-[[2-chloro-4-(ethylsulfonyl)phenyl]thio]-5-(trifluoromethyl)phenyl]acetic acid



(i) **[3-[[dimethylamino]carbonothioyl]oxy]-5-(trifluoromethyl)phenyl]acetic acid**

The product from example 25 step (iv) (0.5 g), dimethylthiocarbamoyl chloride (0.32 ml),
10 DMAP (0.026 g) and triethylamine (0.60 ml) in dry dioxane (10 ml) were stirred at 100 °C for 15 h. The mixture was diluted with water, extracted with ethyl acetate, dried (MgSO₄) and evaporated under reduced pressure to an oil. The oil was purified by flash column chromatography (eluent ether) to give the subtitle compound (0.52 g).

¹H NMR CDCl₃: δ 7.42 (1H, s), 7.26-7.23 (2H, m), 3.72 (5H, m), 3.44 (3H, s), 3.35 (3H,
15 s).

(ii) **[3-[[dimethylamino]carbonyl]thio]-5-(trifluoromethyl)phenyl]acetic acid**

The product from step (i) (0.51 g) in diphenylether (5 ml) was heated at 200 °C for 20 h. The reaction mixture was purified by flash column chromatography (eluent: DCM to diethylether) to give the subtitle compound (0.49 g).

MS: APCI(+ve): 322 (M+H).

(iii) **[3-mercapto-5-(trifluoromethyl)phenyl]acetic acid**

The product from step (ii) (0.49g) was dissolved in methanol (10 ml) and 2M NaOH (10
25 ml) and stirred at RT overnight. The mixture was diluted with 2M HCl, extracted with ethyl acetate, dried (MgSO₄) and evaporated under reduced pressure to a solid (0.30 g)
¹H NMR CDCl₃: δ 7.45 (1H, s), 7.32 (1H, s), 7.27-7.26 (1H, s), 3.76-3.66 (2H, s), 2.91 (1H, s).

(iv) **[3-[[2-chloro-4-(ethylsulfonyl)phenyl]thio]-5-(trifluoromethyl)phenyl]acetic acid**


The title compound was prepared as described in example 2 step (iii) but instead using the product from step (iii) and the product from example 3 step (i).

¹H NMR DMSO-d₆: δ 7.97 (1H, s), 7.81-7.79 (3H, d), 7.73-7.69 (1H, d), 7.01-6.94 (1H, d), 3.63 (2H, s), 3.41-3.30 (2H, q), 1.19-1.06 (3H, t).

MS: APCI-ve 393 (M-CO₂).

Example 59

{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methoxyphenyl}acetic acid



(i) **methyl {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-hydroxyphenyl}acetate**

The subtitle compound was prepared as described in example 2 step (iii) but instead using the product from example 3 step (i) and methyl (3,5-dihydroxyphenyl)acetate.


MS: APCI-ve 383 (M-H).

(ii) **{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methoxyphenyl}acetic acid**

The product from step (i) was taken up in toluene (3 ml) and methanol (1 ml) and TMS-diazomethane (0.6 ml, 2M in diethylether) added, the mixture stirred at RT for 3 h then evaporated under reduced pressure. The residue was taken up in THF (2 ml) and methanol (1 ml) then 3M NaOH (2 ml) added and the mixture stirred at RT for 2 h. The mixture was then acidified to pH 2 and extracted with ethyl acetate. The organics were dried (MgSO₄), evaporated under reduced pressure and then passed onto a Varian NH₂ resin (eluting with ethyl acetate, acetonitrile, methanol, DCM then 20% acetic acid in DCM). The acidic fraction was evaporated under reduced pressure and then purified by RPHPLC to give a white solid.

¹H NMR DMSO-d₆: δ 8.07 (1H, d), 7.82 (1H, dd), 7.13 (1H, d), 6.78 (1H, s), 6.66 (1H, t), 6.63 (1H, s), 3.77 (3H, s), 3.54 (2H, s), 3.37 (3H, q), 1.14 (3H, t).

MS: APCI-ve 383 (M-H).

Example 60**[3-{2-chloro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid****(i) 2-chloro-1-fluoro-4-[(2-fluorobenzyl)sulfonyl]benzene**

The subtitle compound was prepared as described in example 54 step (i) but instead using the 3-chloro-4-fluorobenzenethiol and 1-(bromomethyl)-2-fluorobenzene.

¹H NMR CDCl₃: δ 7.71-7.68 (1H, m), 7.57-7.51 (1H, m), 7.39-7.32 (2H, m), 7.27-7.15 (2H, m), 6.98-6.92 (1H, m), 4.41 (2H, s).


10

(ii) [3-{2-chloro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 8.02-7.94 (1H, m), 7.82-7.55 (2H, m), 7.45-7.12 (7H, m), 4.82-4.79 (2H, s), 3.76 (2H, s).

MS: APCI-ve 457 (M-CO₂).

Example 61**[3-{[3-methyl-5-(phenylsulfonyl)pyridin-2-yl]oxy}-5-(trifluoromethyl)phenyl]acetic acid****(i) 2-chloro-3-methyl-5-(phenylthio)pyridine**

2-Chloro-3-methyl-5-bromopyridine (1.0 g) was added to a stirred solution of butyllithium

(2.5M in hexanes, 1.94ml) in dry THF (20ml) at -78 °C. The mixture was left at -78 °C for

25

5 minutes before treating with diphenyldisulphide (1.06 g). The mixture was allowed to warm to RT. After 1 h, the mixture was quenched with 2M HCl, extracted with ether (discarded) then the aqueous layer basified with saturated sodium hydrogen carbonate solution, extracted with ethyl acetate, dried (MgSO₄) and evaporated under reduced pressure to give a brown oil. The oil was subjected to flash column chromatography (eluent 3:2 DCM / ethyl acetate) to give the subtitle compound (2.30 g).

MS: APCI(-ve): 236 (M+H).

(ii) 2-chloro-3-methyl-5-(phenylsulfonyl)pyridine

The product from step (i) (2.30 g) was dissolved in DCM (10 ml) and TFA (5 ml). The mixture was evaporated under reduced pressure to give a yellow oil. The oil was dissolved in DCM (50 ml) and mCPBA (4.20 g) added and stirred at RT overnight. The solution was then washed with aqueous sodium metabisulphite and aqueous sodium hydrogen carbonate, dried (MgSO₄) and evaporated under reduced pressure to give an oil, which was purified by flash column chromatography (eluent 1:1 isohexane / diethylether) to give the subtitle compound (0.89 g).


¹H NMR CDCl₃: δ 8.75-8.74 (1H, s), 8.02-7.89 (2H, m), 7.69-7.49 (3H, m), 7.26 (1H, s), 2.31 (3H, s).

(iii) [3-{[3-methyl-5-(phenylsulfonyl)pyridin-2-yl]oxy}-5-(trifluoromethyl)phenyl]acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from step (ii).

¹H NMR DMSO-d₆: δ 8.54-8.53 (1H, s), 8.28 (1H, s), 8.01-7.98 (2H, m), 7.73-7.42 (6H, m), 3.74 (2H, s), 2.27 (3H, s).

MS: APCI(-ve) 450 (M-H).

Example 62**[3-[2-chloro-4-(morpholin-4-ylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid****(i) 4-[(3-chloro-4-fluorophenyl)sulfonyl]morpholine**

4-fluoro-3-chlorobenzenesulphonyl chloride (0.9 g) was stirred in dry DCM (10 ml) and morpholine (0.69 ml) added. The mixture was allowed to stir at RT for 1 h and then quenched with water, extracted with DCM, dried (MgSO₄) and evaporated under reduced pressure to give a white solid (1.10 g).


¹H NMR CDCl₃: δ 7.86-7.83 (1H, m), 7.69-7.64 (1H, m), 7.36-7.26 (1H, t), 3.78-3.75 (4H, m), 3.01 (4H, m).

(ii) [3-[2-chloro-4-(morpholin-4-ylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 12.52 (1H, bs), 7.95-7.93 (1H, m), 7.73-7.33 (4H, m), 7.24-7.21 (1H, d), 3.76 (2H, s), 3.64 (4H, m), 2.93 (4H, m).

MS: APCI-ve 434 (M-CO₂).

Example 63**[3-(4-benzoyl-2-chlorophenoxy)-5-(trifluoromethyl)phenyl]acetic acid**

(i) **(3-chloro-4-fluorophenyl)(phenyl)methanone**

3-chloro-4-fluorobenzoyl chloride (1.0 g), benzene (2 ml) and ferric chloride (0.28 g) were heated to reflux for 16 h then diluted with water, extracted with ethyl acetate and the organics dried (MgSO₄) and evaporated under reduced pressure to give the subtitle compound as a brown solid (0.8 g).

¹H NMR CDCl₃: δ 7.91-7.88 (1H, d), 7.77-7.48 (6H, m), 7.28-7.22 (1H, t).

(ii) **[3-(4-benzoyl-2-chlorophenoxy)-5-(trifluoromethyl)phenyl]acetic acid**


The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: 7.95-7.93 (1H, m), 7.78-7.49 (7H, m), 7.25 (2H, s), 7.20-7.18 (1H, d), 3.60 (2H, s).

MS: APCI-ve 389 (M-CO₂).

Example 64

[3-{2-chloro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid



(i) **2-chloro-1-fluoro-4-[(3-fluorobenzyl)sulfonyl]benzene**

The subtitle compound was prepared as described in example 54 step (i) but instead using 3-chloro-4-fluorobenzenethiol and 1-(bromomethyl)-3-fluorobenzene.

¹H NMR CDCl₃: δ 7.71-7.68 (1H, m), 7.57-7.51 (1H, m), 7.39-7.32 (2H, m), 7.27-7.15 (2H, m), 6.98-6.92 (1H, m), 4.41 (2H, s).

(ii) **[3-{2-chloro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid**


The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.75 (1H, m), 7.68–6.97 (9H, m), 4.81 (2H, s), 3.65 (2H, s).

MS: APCI–ve 501 (M–H).

Example 65

5 **[3-bromo-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl]acetic acid**




The title compound was prepared as described in example 2 step (iii) but instead using the product from example 55 step (v) and the product from example 24 step (i).

¹H NMR DMSO-d₆: 8.05–7.99 (3H, m), 7.80–7.62 (4H, m), 7.32 (1H, s), 7.21–7.17 (2H, m), 7.02 (1H, s), 3.35 (2H, s).

MS: APCI–ve 419 (M–CO₂).

Example 66

15 **[3-{2-fluoro-4-[(4-fluorophenyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid**



(i) 1,2-difluoro-4-[(4-fluorophenyl)sulfonyl]benzene

The title compound was prepared as described in example 29 step (i) but instead using 3,4-difluorosulfonyl chloride and fluorobenzene.

¹H NMR CDCl₃: δ 7.98–7.93 (2H, m), 7.78–7.70 (2H, m), 7.36–7.19 (3H, m).

(ii) [3-{2-fluoro-4-[(4-fluorophenyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid


The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 8.12-8.08 (3H, m), 7.82-7.80 (1H, d), 7.53-7.44 (4H, m), 7.37 (1H, s), 7.27-7.23 (1H, t), 3.71 (2H, s).

MS: APCI-ve 471 (M-H).

5 **Example 67**

{3-chloro-5-[4-(ethylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid



(i) **4-bromo-1-(ethylsulfonyl)-2-(trifluoromethyl)benzene**

4-Bromo-1-(ethylthio)-2-(trifluoromethyl)benzene (3.80 g) was dissolved in DCM (50 ml)
10 and MCPBA (5.71 g) added and stirred at RT overnight. The solution was then washed
with aqueous sodium metabisulphite and aqueous sodium hydrogen carbonate, dried
(MgSO₄) and evaporated under reduced pressure to give a solid, which was purified by
flash column chromatography (eluent 1:1 isohexane / DCM) to give the subtitle compound
(4.10 g).


15 ¹H NMR CDCl₃: δ 8.13-7.87 (3H, m), 3.31-3.24 (2H, q), 1.34-1.26 (3H, t).

(ii) **{3-chloro-5-[4-(ethylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the
product from example 18 step (iv) and the product from step (i).

20 ¹H NMR DMSO-d₆: δ 8.16-8.14 (1H, d), 7.63-7.62 (1H, s), 7.41-7.38 (1H, d), 7.29-7.12
(3H, m), 3.59 (2H, s), 3.42-3.31 (2H, q), 1.18-1.14 (3H, t).

MS: APCI-ve 377 (M-CO₂).

Example 68**{3-chloro-5-[5-chloro-2-fluoro-4-(pyrrolidin-1-ylcarbonyl)phenoxy]phenyl}acetic acid****(i) 1-(2-chloro-4,5-difluorobenzoyl)pyrrolidine**

- 2-chloro-4,5-difluorobenzoic acid (1.0 g) in DCM (10 ml) was treated with oxalyl chloride (0.45 ml) followed by a drop of DMF. The mixture was stirred at RT for 1 h before evaporating under reduced pressure. The solid was dissolved in DCM (20 ml) and pyrrolidine (2 ml) was added and stirred at RT overnight. The mixture was diluted with water, extracted with DCM, dried (MgSO₄) and evaporated under reduced pressure to give an oil (1.45 g).


¹H NMR CDCl₃: δ 7.27-7.23 (1H, m), 7.19-7.15 (1H, m), 3.66-3.62 (2H, t), 3.23-3.20 (2H, t), 2.05-1.88 (4H, m).

(ii) {3-chloro-5-[5-chloro-2-fluoro-4-(pyrrolidin-1-ylcarbonyl)phenoxy]phenyl}acetic acid

- The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.59-7.56 (1H, d), 7.40-7.38 (1H, d), 7.14 (1H, s), 7.02-7.01 (1H, s), 6.94 (1H, s), 3.44 (4H, m), 3.19-3.15 (2H, t), 1.90-1.81 (4H, m).

- MS: APCI+ve 412 (M+H).

Example 69**{3-cyano-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid**

(i) {3-bromo-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid


The subtitle compound was prepared as described in example 56 step (ii) but instead using the product of example 56 step (i) and example 24 step (i). The product was used crude without further characterisation.

(ii) {3-cyano-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid

The title compound was prepared as described in example 56 step (iii) but instead using zinc cyanide and the product from step (i).

¹H NMR DMSO-d₆: 8.08-8.00 (3H, m), 7.80-7.55 (6H, m), 7.34 (1H, s), 7.29-7.18 (1H, t), 3.53 (2H, s).


MS: APCI-ve 366 (M-CO₂).

Example 70**{3-chloro-5-[2-fluoro-4-[(4-fluorophenyl)sulfonyl]phenoxy]phenyl}acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from example 66 step (i).

¹H NMR DMSO-d₆: δ 8.10-8.00 (3H, m), 7.80-7.78 (1H, d), 7.50-7.46 (2H, t), 7.24-7.02 (2H, m), 6.87 & 6.82 (2H, 2xs), 3.41-3.39 (2H, s).

MS: APCI-ve 437 (M-H).

Example 71**{3-chloro-5-[2-cyano-4-(ethylsulfonyl)phenyl]thio}phenyl}acetic acid**

(i) (3-chloro-5-mercaptophenyl)acetic acid

The subtitle compound was prepared as described in example 58 steps (i) to (iii) but instead using the product from example 18 step (iv).


¹H NMR CDCl₃:- δ 7.32-7.31 (1H, s), 7.26 (1H, s), 7.08-7.07 (1H, s), 3.56 (2H, s), 2.9 (1H, s).

(ii) (3-chloro-5-[[2-cyano-4-(ethylsulfonyl)phenyl]thio]phenyl)acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from step (i) and the product from example 12 step (i).

¹H NMR DMSO-d₆: δ 8.36 (1H, s), 8.02-7.99 (1H, m), 7.59-7.48 (3H, m), 7.25-7.22 (1H, m), 3.54 (2H, s), 3.40 (2H, q), 1.13-1.08 (3H, t).


MS: APCI-ve 394 (M-H).

Example 72**(3-chloro-5-[[4-(ethylsulfonyl)-2-(trifluoromethyl)phenyl]thio]phenyl)acetic acid**

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 71 step(i) and the product from example 2 step (ii).

¹H NMR DMSO-d₆: δ 12.53 (1H, bs), 8.21-8.20 (1H, s), 8.07-8.04 (1H, d), 7.57-7.53 (2H, m), 7.47 (1H, s), 7.34-7.32 (1H, d), 3.69 (2H, s), 3.30 (3H, s).


MS: APCI-ve 379 (M-CO₂).

Example 73**(3-chloro-5-([2-fluoro-4-(phenylsulfonyl)phenyl]thio)phenyl)acetic acid**

The title compound was prepared as described in example 1 step vi) but instead using the product from example 71 step (i) and the product from example 24 step (i).

¹H NMR DMSO-d₆: δ 12.51 (1H, s), 8.00-7.91 (3H, m), 7.73-7.60 (4H, m), 7.49-7.29 (3H, m), 7.24-7.18 (1H, t), 3.65 (2H, s).

MS: APCI-ve 435 (M-H).

Example 74**[3-(4-benzoyl-3,5-difluorophenoxy)-5-chlorophenyl]acetic acid****(i) phenyl(2,4,6-trifluorophenyl)methanone**

2,4,6-trifluorobenzoyl chloride (5.0 g), benzene (5 ml) and ferric chloride (1.39 g) were heated at 80 °C for 16 h, then allowed to cool to room temperature. The reaction mixture was diluted with water, extracted with ethyl acetate (x 2) and the combined organic extracts washed with brine, dried (MgSO₄) and evaporated under reduced pressure (5.80 g).

¹H NMR CDCl₃: δ 7.86-7.84 (2H, m), 7.66-7.61 (1H, m), 7.52-7.47 (2H, m), 6.81-6.74 (2H, m).

(ii) [3-(4-benzoyl-3,5-difluorophenoxy)-5-chlorophenyl]acetic acid


The title compound was prepared as described in example 2 step (iii) but instead using the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.87-7.68 (3H, m), 7.62-7.55 (2H, t), 7.26-7.24 (2H, m), 7.13-7.12 (1H, s), 7.01-6.92 (2H, d), 3.62 (2H, s).

MS: APCI+ve 357 (M-CO₂).

5 **Example 75**

{3-chloro-5-[2-chloro-4-(4-fluorobenzoyl)phenoxy]phenyl}acetic acid



(i) **(3-chloro-4-fluorophenyl)(4-fluorophenyl)methanone**

The subtitle compound was prepared as described in example 74 step (i) but instead using
10 3-chloro-4-fluorobenzoyl chloride and fluorobenzene.

¹H NMR CDCl₃-d₆: δ 7.88-7.78 (3H, m), 7.57-7.53 (1H, m), 7.29-7.15 (3H, m).

(ii) **{3-chloro-5-[2-chloro-4-(4-fluorobenzoyl)phenoxy]phenyl}acetic acid**


The title compound was prepared as described in example 2 step (iii) but instead using
15 the product from example 18 step (iv) and the product from step (i).

¹H NMR DMSO-d₆: δ 7.92-7.84 (3H, m), 7.72-7.69 (1H, d), 7.44-7.39 (2H, m), 7.21-7.17 (2H, m), 7.10-7.08 (1H, m), 7.00 (1H, s), 3.55 (2H, s).

MS: APCI+ve 373 (M-CO₂).

20 **Example 76**

{3-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}-5-methylphenyl}acetic acid



(i) **{3-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}-5-hydroxyphenyl}acetic acid**

The subtitle compound was prepared as described in example 2 step (iii) but instead using
25 3,5-dihydroxyphenylacetic acid and the product from example 24 step (i).

MS: APCI-ve 415 (M-H).

(ii) (3-[2-fluoro-4-(phenylsulfonyl)phenoxy]-5-[(trifluoromethyl)sulfonyl]oxy}phenyl) acetic acid

- 5 The product from step (i) (4.16 g) in dry DCM (20 ml) was treated with pyridine (0.81 ml) and cooled to 0 °C before adding trifluoromethanesulphonic anhydride (1.68 ml). The mixture was stirred at RT overnight and then diluted with water, extracted with DCM, dried (MgSO₄) and evaporated under reduced pressure (2.09 g).
1H NMR CDCl₃-d₆: δ 7.97-7.95 (2H, d), 7.80-7.72 (2H, m), 7.65-7.52 (3H, m), 7.18-7.10 (1H, t), 7.05-6.85 (3H, s), 3.71 (3H, s), 3.63 (2H, s).
- 10

(iii) {3-[2-fluoro-4-(phenylsulfonyl)phenoxy]-5-methylphenyl}acetic acid


- The title compound was prepared by treating the product from step (ii) (0.25 g) in dry dioxane (10 ml) with bisdiphenylphosphinoferrocene palladium (0.02 g) and 2.0M
15 dimethylzinc in toluene (0.40 ml). The mixture was heated to reflux for 3 h, partitioned between water and ethyl acetate, the organics separated, dried (MgSO₄) and evaporated under reduced pressure to an oil. The oil was dissolved in methanol (10 ml), 2M NaOH (10 ml) added and stirred at RT overnight. The mixture was diluted with water, extracted with ether (discarded). The aqueous layer was acidified with 2M HCl, extracted with ethyl
20 acetate, dried (MgSO₄) and evaporated under reduced pressure to an oil, which was purified by RPHPLC to give a white solid (0.085g).
1H NMR DMSO-d₆: δ 8.03-7.97 (3H, m), 7.77-7.60 (4H, m), 7.13-7.07 (1H, t), 6.94 (1H, s), 6.81 (2H, s), 3.34 (2H, s), 2.26 (3H, s).

MS: APCI-ve 355 (M-CO₂).

25

Example 77

{3-ethyl-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid




The title compound was prepared as described in example 76 step (iii) but instead using the product of example 76 step (ii) and 2.0M diethylzinc in toluene.

¹H NMR DMSO-d₆: δ 8.04-7.97 (3H, m), 7.78-7.60 (4H, m), 7.12-7.07 (1H, t), 6.98 (1H, s), 6.86-6.84 (2H, d), 3.48 (2H, s), 2.61-2.51 (2H, q), 1.17-1.12 (3H, t).

5 MS: APCI-ve 369 (M-CO₂).

Example 78

[3-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid



10


The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from example 34 step (i).

¹H NMR DMSO-d₆: δ 7.92 (1H, d), 7.61 (1H, dd), 7.55 (1H, s), 7.35 (2H, d), 7.27-7.13 (5H, m), 4.77 (2H, s), 3.76 (2H, s).

15 MS: MM-ve 501 (M-H).

Example 79

[3-{2-cyano-4-(phenylsulfonyl)phenoxy}-5-(trifluoromethyl)phenyl]acetic acid




20 The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from example 44 step (i).

¹H NMR DMSO-d₆: δ 12.57 (1H, s), 8.62 (1H, d), 8.17 (1H, dd), 8.03 (2H, dt), 7.76-7.61 (5H, m), 7.54 (1H, s), 7.04 (1H, d), 3.77 (2H, s).

MS: MM-ve 416 (M-CO₂).


25

Example 80**{5-[2-chloro-4-(ethylsulfonyl)phenoxy]biphenyl-3-yl}acetic acid**

The product from example 55 step (vi) (0.45 g), phenyl boronic acid (0.190 g), sodium carbonate (0.44 g) and bisdiphenylphosphinoferrocene palladium (II) (0.04 g) in dry dioxane (20 ml) were heated to 80 °C for 20 h. Mixture diluted with 2M HCl, extracted with ethyl acetate, dried (MgSO₄) and evaporated under reduced pressure to an oil, which was purified by RPHPLC to give a cream solid (0.23 g).

¹H NMR DMSO-d₆: δ 8.07 (1H, s), 7.82-7.79 (1H, d), 7.69-7.66 (2H, d), 7.50-7.35 (5H, m), 7.18-7.06 (2H, m), 3.69 (2H, s), 3.39-3.31 (2H, q), 1.14-1.09 (3H, t).


MS: MM-ve 385 (M-CO₂).

Example 81**{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-pyridin-2-yl}phenyl}acetic acid**

The product from example 55 step (vi) (0.45 g), 2-pyridyl zinc bromide (0.89 ml) and bisdiphenylphosphinoferrocene palladium (II) (0.04 g) in dry dioxane (20 ml) were heated to 90 °C for 20 h. Mixture diluted with water, extracted with DCM, dried (MgSO₄) and evaporated under reduced pressure to an oil, which was purified by RPHPLC to give a white solid (3 mg).

¹H NMR DMSO-d₆: δ 8.65-8.64 (1H, m), 8.09-7.72 (6H, m), 7.39-7.36 (1H, m), 7.19-7.15 (2H, m), 3.66 (2H, s), 3.39-3.35 (2H, q), 1.14-1.10 (3H, t).

MS: MM+ve 432 (M+H).

Example 82**{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-[2-(dimethylamino)ethoxy]phenyl}acetic acid****5 (i) methyl {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-hydroxyphenyl}acetate**

Methyl-3,5-dihydroxyphenyl acetate (0.20 g), cesium carbonate (1.08 g) and the product from example 3 step (i) in dry NMP were heated at 50 °C for 4 h. 2M HCl was added and extracted with ethyl acetate. The organics were dried (MgSO₄) and evaporated under reduced pressure to a brown oil, which was purified by flash column chromatography (eluent 1:1 ethyl acetate / isohexane) to give a mixture of the mono- and bis-coupled products used in the next step without further purification.

MS: MM-ve 383 (M-H).

15 (ii) methyl {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-[2-(dimethylamino)ethoxy]phenyl} acetate

Potassium carbonate (0.46 g) was added to a solution of the product from step (i) (1.10 mmol) and 2-dimethylamino ethyl chloride hydrochloride (0.16 g) in DMF at RT. After 1 h no reaction was evident so the mixture was heated to 60 °C for 18 h. Water was added and the mixture extracted with ethyl acetate, washed (brine) and the organics dried (MgSO₄) and concentrated to a green oil which was purified by flash column chromatography (eluent 1% triethylamine and 2% methanol in ethyl acetate) to give the subtitle compound as a colourless oil (100 mg).

MS: MM+ve 456 (M+H).

25 (iii) {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-[2-(dimethylamino)ethoxy]phenyl}acetic acid

1M sodium hydroxide (0.44 ml) was added to a solution of the product from step (ii) (100 mg) in 1:1 THF/methanol (6 ml) and stirred for 48 h. The mixture was evaporated under


reduced pressure and purified by RPHPLC to give the title compound as a white solid (0.04g).

¹H NMR MeOD: δ 8.00 (1H, d), 7.75 (1H, dd), 7.41 (1H, d), 6.87 (1H, s), 6.69 (1H, s), 6.59 (1H, t), 4.27 (2H, t), 3.46 (2H, s), 3.34 (2H, t), 3.22 (2H, q), 2.79 (6H, s), 1.23 (3H, t).

5 MS: MM+ve 442 (M+H).

Example 83

[3-{2-chloro-4-[(pyridin-2-ylmethyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid



10

(i) 2-[[3-chloro-4-fluorophenyl]thio]methyl}pyridine

2-Picolyl chloride hydrochloride (3.03 g) was added to a stirred suspension of 3-chloro-4-fluorobenzenethiol (3.0 g) and cesium carbonate (12.0 g) in DMF (50 ml) and the mixture stirred at RT overnight. Mixture poured into water, organics extracted into ether and the ether extracts washed (brine), dried (MgSO₄) and evaporated under reduced pressure to a green oil (4.0 g).

15

¹H NMR DMSO-d₆: δ 8.48 (1H, d), 7.74 (1H, td), 7.62-7.58 (1H, m), 7.43-7.32 (3H, m), 7.26 (1H, ddd), 4.36 (2H, s).

(ii) 2-[[3-chloro-4-fluorophenyl]sulfonyl]methyl}pyridine

TFA (0.59 ml) was added to a solution of the product from step (i) (2.0 g) in DCM (50 ml). MCPBA (6.6 g) was then added portionwise to the solution followed by further DCM (20 ml). The mixture was stirred at RT for 2 h then DCM added (150 ml) and the mixture washed with aqueous sodium hydrogen carbonate then brine. The organics were dried (MgSO₄) and evaporated under reduced pressure and the residue purified by flash column chromatography (eluent 1:1 i-hexane / ethyl acetate to 10% ethanol / DCM) to give the product (1.3 g) as a white solid.

25

¹H NMR DMSO-d₆: δ 8.42 (1H, ddd), 7.92 (1H, dd), 7.81 (1H, td), 7.70-7.61 (2H, m), 7.40 (1H, d), 7.34 (1H, ddd), 4.92 (2H, s).

(iii) [3-{2-chloro-4-[(pyridin-2-ylmethyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid

The title compound was prepared as described in example 2 step (iii) but instead using the product from example 25 step (iv) and the product from step (ii).

¹H NMR DMSO-d₆: δ 8.43 (1H, dd), 7.89 (1H, d), 7.81 (1H, td), 7.61 (1H, dd), 7.55 (1H, s), 7.42 (1H, d), 7.37-7.32 (3H, m), 7.20 (1H, d), 4.91 (2H, s), 3.77 (2H, s).

MS: MM+ve 486 (M+H).

Pharmacological Data

Ligand Binding Assay

[³H]PGD₂ was purchased from Perkin Elmer Life Sciences with a specific activity of 100-210Ci/mmol. All other chemicals were of analytical grade.

HEK cells expressing rhCRT_{h2} / Gα16 were routinely maintained in DMEM containing 10% Foetal Bovine Serum (HyClone), 1mg/ml geneticin, 2mM L-glutamine and 1% non-essential amino acids. For the preparation of membranes, the adherent transfected HEK cells were grown to confluence in two layer tissue culture factories (Fisher, catalogue number TKT-170-070E). Maximal levels of receptor expression were induced by addition of 500mM sodium butyrate for the last 18 hours of culture. The adherent cells were washed once with phosphate buffered saline (PBS, 50ml per cell factory) and detached by the addition of 50ml per cell factory of ice-cold membrane homogenisation buffer [20mM HEPES (pH 7.4), 0.1mM dithiothreitol, 1mM EDTA, 0.1mM phenyl methyl sulphonyl fluoride and 100µg/ml bacitracin]. Cells were pelleted by centrifugation at 220xg for 10 minutes at 4°C, re-suspended in half the original volume of fresh membrane homogenisation buffer and disrupted using a Polytron homogeniser for 2 x 20 second bursts keeping the tube in ice at all times. Unbroken cells were removed by centrifugation at 220xg for 10 minutes at 4°C and the membrane fraction pelleted by centrifugation at 90000xg for 30 minutes at 4°C. The final pellet was re-suspended in 4 ml

of membranous homogenisation buffer per cell factory used and the protein content determined. Membranes were stored at -80°C in suitable aliquots.

All assays were performed in Corning clear bottomed, white 96-well NBS plates (Fisher). Prior to assay, the HEK cells membranes containing CRTh2 were coated onto SPA PVT WGA beads (Amersham). For coating membranes were incubated with beads at typically $25\mu\text{g}$ membrane protein per mg beads at 4°C with constant agitation overnight. (The optimum coating concentrations were determined for each batch of membranes) The beads were pelleted by centrifugation ($800\times g$ for 7 minutes at 4°C), washed once with assay buffer (50mM HEPES pH 7.4 containing 5mM magnesium chloride) and finally re-suspended in assay buffer at a bead concentration of 10mg/ml.


Each assay contained $20\mu\text{l}$ of 6.25nM [^3H]PGD₂, $20\mu\text{l}$ membrane saturated SPA beads both in assay buffer and $10\mu\text{l}$ of compound solution or 13,14-dihydro-15-keto prostaglandin D₂ (DK-PGD₂, for determination of non-specific binding, Cayman chemical company).

Compounds and DK-PGD₂ were dissolved in DMSO and diluted in the same solvent to 100x the required final concentration. Assay buffer was added to give a final concentration of 10% DMSO (compounds were now at 10x the required final concentration) and this was the solution added to the assay plate. The assay plate was incubated at room temperature for 2 hours and counted on a Wallac Microbeta liquid scintillation counter (1 minute per well).

Compounds of formula (I) have an IC_{50} value of less than ($<$) $10\mu\text{M}$. Specifically Example 7 has a pIC_{50} value of 8.10, example 9 has a pIC_{50} value of 7.85 and example 11 has a pIC_{50} value of 8.05

CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



in which:

- 10 A and D are independently selected from hydrogen, halogen, CN, OR³, S(O)nR³ (where n is 0, 1 or 2), nitro, aryl, heteroaryl, C₃₋₈cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by halogen atoms;

E is O, S, NR⁶ or CR¹R²;

15

V is N or C(H);

W is nitrogen or W is a carbon atom substituted by hydrogen, halogen, CN, SO₂R⁹, or C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms);

20

X is nitrogen or X is a carbon atom substituted by hydrogen, halogen, CN, SO₂R⁹, or C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms);

Y is selected from hydrogen, CN, halogen, C₁₋₆ alkyl (the latter being optionally substituted by one or more halogen atoms);

25

Z is selected from hydrogen, halogen, CN, $\text{SO}_2\text{NR}^4\text{R}^5$, CONR^4R^5 , COR^6 , CO_2R^6 , SO_2R^6 or OR^6 ;

R^1 and R^2 independently represent a hydrogen atom, halogen, or a C_{1-6} alkyl group;

or

R^1 and R^2 together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR^6 and itself optionally substituted by one or more C_{1-3} alkyl or halogen;

R^3 is hydrogen, C_{1-6} alkyl (optionally substituted by halogen or NR^4R^5) or SO_2R^7 ;

R^4 and R^5 independently represent hydrogen, C_{3-8} cycloalkyl or C_{1-6} alkyl the latter two groups being optionally substituted by one or more substituents independently selected from halogen, CN, C_{3-7} cycloalkyl, C_{1-6} alkyl, OR^3 and NR^7R^8 , aryl, heteroaryl, $\text{S(O)}_n\text{R}^9$ (where $n = 0, 1$ or 2), CONR^7R^8 , $\text{NR}^3\text{COR}^{10}$, $\text{SO}_2\text{NR}^4\text{R}^5$ and $\text{NR}^3\text{SO}_2\text{R}^9$;

or

R^4 and R^5 together with the nitrogen atom to which they are attached can form a 3-8 membered saturated ring optionally containing one or more atoms selected from O, N, S(O)_n (where $n = 0, 1$ or 2), NR^3 , and itself optionally substituted by one or more halogen, OR^3 , C_{3-8} cycloalkyl or C_{1-6} alkyl, the latter two groups being optionally substituted by one or more halogen;

R^6 represents aryl, heteroaryl, C_{3-8} cycloalkyl or C_{1-6} alkyl all of which being optionally substituted by one or more substituents independently selected from halogen, C_{3-7} cycloalkyl, C_{1-6} alkyl, OR^3 , CN, NR^7R^8 , aryl, heteroaryl, $\text{S(O)}_n\text{R}^9$ (where $n = 0, 1$ or 2), CONR^7R^8 , $\text{NR}^3\text{COR}^{10}$, $\text{SO}_2\text{NR}^4\text{R}^5$ and $\text{NR}^3\text{SO}_2\text{R}^9$;

R⁷ independently represents a hydrogen atom or C₁-C₆ alkyl (the alkyl group can be optionally substituted by one or more halogen atoms);

R⁸ is hydrogen, C₁₋₄ alkyl, -COC₁-C₄ alkyl, CO₂C₁-C₄alkyl or CONR⁵C₁-C₄alkyl;

R⁹ represents aryl, heteroaryl, C₃₋₇ cycloalkyl or C₁₋₆alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C₃₋₇ cycloalkyl, aryl, heteroaryl OR⁶ and NR¹⁰R¹¹, S(O)_nR⁶ (where n = 0, 1 or 2), CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁴R⁵ and NR⁶SO₂R⁷;

R¹⁰ and R¹¹ independently represent aryl or heteroaryl, hydrogen, C₃₋₇ cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C₃₋₇ cycloalkyl, aryl, heteroaryl, OH, OR⁹ and NR⁴R⁵, S(O)_nR⁶ (where n = 0, 1 or 2), CONR⁴R⁵, NR⁶COR⁷, SO₂NR⁴R⁵ and NR⁶SO₂R⁷;

or

R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)_n (where n = 0, 1 or 2), NR⁸, and itself optionally substituted by halogen or C₁-C₃ alkyl,

provided that:

- A and D cannot both be hydrogen;
- A and D cannot be aryl substituted in the *para*-position by -S(O)_n-, where n is 0, 1 or 2;
- when V, W and X are all carbon then all of the substituents on the phenyl ring (V, W, X, Y and Z) cannot be hydrogen.

2. A compound according to claim 1 in which A is hydrogen, halogen, CN, OR³, aryl, heteroaryl or C₁₋₆alkyl, the latter group being optionally substituted by one or more halogen atoms.

3. A compound according to claim 1 in which A is hydrogen, halogen or C₁₋₆alkyl, the latter group being optionally substituted by one or more halogen atoms.
4. A compound according to claim 1 in which D is hydrogen, halogen or C₁₋₆alkyl, the latter group being optionally substituted by one or more halogen atoms.
5. A compound according to any of claims 1 to 4 in which where D is not hydrogen then A is hydrogen; where A is not hydrogen then D is hydrogen.
6. A compound according to claims 1 to 5 in which E is oxygen or sulfur.
7. A compound according to claims 1 to 5 in which E is oxygen.
8. A compound according to any one of claims 1 to 7 in which V is C(H).
9. A compound according to any one of claims 1 to 8 in which W is a carbon atom substituted by hydrogen, halogen, CN or C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms).
10. A compound according to any one of claims 1 to 8 in which W is a carbon atom substituted by hydrogen, halogen or C₁₋₃ alkyl (the latter group being optionally substituted by halogen atoms).
11. A compound according to any one of claims 1 to 8 in which W is C(H).
12. A compound according to any one of claims 1 to 11 in which X is a carbon atom substituted by hydrogen or halogen.
13. A compound according to any of claims 1 to 11 in which X is C(H).
14. A compound according to any one of claim 1 to 13 in which Y is halogen, cyano or C₁₋₃ alkyl optionally substituted by one or more halogen atoms.

15. A compound according to any one of claims 1 to 14 in which Z is selected from SO_2R^9 , $\text{SO}_2\text{NR}^4\text{R}^5$, CONR^4R^5 or COR^6
16. A compound according to any one of claim 1 to 15 in which R^1 and R^2 are both hydrogen, or one of R^1 or R^2 is methyl and the other is hydrogen.
17. A compound of formula (I) selected from:
- {4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
{4-chloro-3-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
10 {4-chloro-3-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
{4-chloro-3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
{4-chloro-3-[4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
2-{4-chloro-3-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}propanoic acid;
(4-chloro-3-{2-chloro-4-[(dimethylamino)sulfonyl]phenoxy}phenyl)acetic acid;
15 [4-chloro-3-(3-cyanophenoxy)phenyl]acetic acid;
{4-chloro-3-[2-fluoro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
{4-chloro-3-[4-(ethylsulfonyl)-2-fluorophenoxy]phenyl}acetic acid;
{4-chloro-3-[2-cyano-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
{4-chloro-3-[2-cyano-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
20 {4-chloro-3-[4-(methylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid;
{4-chloro-3-[2-cyano-5-(trifluoromethyl)phenoxy]phenyl}acetic acid;
(4-chloro-3-{2-fluoro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
[3-(4-benzoyl-2-fluorophenoxy)-4-chlorophenyl]acetic acid;
(4-chloro-3-{2-chloro-4-[(isobutylamino)carbonyl]phenoxy}phenyl)acetic acid;
25 {3-chloro-5-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
{3-chloro-5-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-fluorophenyl}acetic acid;
{3-fluoro-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
{3-[2-chloro-4-(ethylsulfonyl)phenoxy]-4-fluorophenyl}acetic acid;
30 {4-fluoro-3-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
{4-chloro-3-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
[3-[2-chloro-4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;

- [3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 {3-chloro-5-[2-fluoro-4-(methylsulfonyl)phenoxy]phenyl}acetic acid;
 {3-chloro-5-[2-cyano-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;
 {3-chloro-5-[2-chloro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 5 {3-chloro-5-[4-(ethylsulfonyl)-2-fluorophenoxy]phenyl}acetic acid;
 {3-chloro-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 [3-{2-fluoro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 (3-chloro-5-{4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
 (3-chloro-5-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
 10 {3-chloro-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
 {3-chloro-5-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
 [3-[2-fluoro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 [3-[2-chloro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 [3-[4-(ethylsulfonyl)-2-fluorophenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 15 [3-[2-cyano-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 [3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 {3-[4-(benzylsulfonyl)-2-chlorophenoxy]-5-chlorophenyl}acetic acid;
 {3-chloro-5-[4-(phenylsulfonyl)-2-(trifluoromethyl)phenoxy]phenyl}acetic acid;
 {3-chloro-5-[2-cyano-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 20 {3-[4-(benzylsulfonyl)-2-fluorophenoxy]-5-chlorophenyl}acetic acid;
 (3-chloro-5-{2-fluoro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
 {3-[4-(benzylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-chlorophenyl}acetic acid;
 (3-chloro-5-{2-fluoro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}phenyl)acetic acid;
 (3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid;
 25 2-[3-[4-(ethylsulfonyl)-2-(trifluoromethyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic
 acid;
 2-[3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid;
 2-[3-[2-chloro-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]propanoic acid;
 2-[3-[2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy]-5-(trifluoromethyl)phenyl]
 30 propanoic acid;
 (3-chloro-5-{4-[(4-chlorobenzyl)sulfonyl]-2-fluorophenoxy}phenyl)acetic acid;
 {3-bromo-5-[2-chloro-4-(ethylsulfonyl)phenoxy]phenyl}acetic acid;

- {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methylphenyl}acetic acid;
 methyl 3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-cyanobenzoate;
 [3-{{2-chloro-4-(ethylsulfonyl)phenyl}thio}-5-(trifluoromethyl)phenyl]acetic acid;
 {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-methoxyphenyl}acetic acid;
 5 [3-{2-chloro-4-[(2-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 [3-{{3-methyl-5-(phenylsulfonyl)pyridin-2-yl}oxy}-5-(trifluoromethyl)phenyl]acetic acid;
 [3-[2-chloro-4-(morpholin-4-ylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 [3-(4-benzoyl-2-chlorophenoxy)-5-(trifluoromethyl)phenyl]acetic acid;
 [3-{2-chloro-4-[(3-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 10 {3-bromo-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 [3-{2-fluoro-4-[(4-fluorophenyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 {3-chloro-5-[4-(ethylsulfonyl)-3-(trifluoromethyl)phenoxy]phenyl}acetic acid;
 {3-chloro-5-[5-chloro-2-fluoro-4-(pyrrolidin-1-ylcarbonyl)phenoxy]phenyl}acetic acid;
 {3-cyano-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 15 (3-chloro-5-[2-fluoro-4-[(4-fluorophenyl)sulfonyl]phenoxy]phenyl)acetic acid;
 (3-chloro-5-[[2-cyano-4-(ethylsulfonyl)phenyl]thio]phenyl)acetic acid;
 (3-chloro-5-[[4-(ethylsulfonyl)-2-(trifluoromethyl)phenyl]thio]phenyl)acetic acid;
 (3-chloro-5-[[2-fluoro-4-(phenylsulfonyl)phenyl]thio]phenyl)acetic acid;
 [3-(4-benzoyl-3,5-difluorophenoxy)-5-chlorophenyl]acetic acid;
 20 {3-chloro-5-[2-chloro-4-(4-fluorobenzoyl)phenoxy]phenyl}acetic acid;
 {3-[2-fluoro-4-(phenylsulfonyl)phenoxy]-5-methylphenyl}acetic acid;
 {3-ethyl-5-[2-fluoro-4-(phenylsulfonyl)phenoxy]phenyl}acetic acid;
 [3-{2-chloro-4-[(4-fluorobenzyl)sulfonyl]phenoxy}-5-(trifluoromethyl)phenyl]acetic acid;
 [3-[2-cyano-4-(phenylsulfonyl)phenoxy]-5-(trifluoromethyl)phenyl]acetic acid;
 25 {5-[2-chloro-4-(ethylsulfonyl)phenoxy]biphenyl-3-yl}acetic acid;
 {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-pyridin-2-ylphenyl}acetic acid;
 {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-[2-(dimethylamino)ethoxy]phenyl}acetic acid
 [3-[2-chloro-4-[(pyridin-2-ylmethyl)sulfonyl]phenoxy]-5-(trifluoromethyl)phenyl]acetic
 acid
 30 and pharmaceutically acceptable salts thereof.

18. A compound of formula (I) according to any one of claims 1 to 17 for use in therapy.
19. A method of treating a disease mediated by prostaglandins, which comprises
5 administering to a patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt as defined in claims 1 to 17.
20. A method of treating a disease mediated by prostaglandin D2, which comprises
10 administering to a patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt as defined in claims 1 to 17.
21. A method of treating a respiratory disease, such as asthma and rhinitis, in a patient
suffering from, or at risk of, said disease, which comprises administering to the patient a
therapeutically effective amount of a compound of formula (I), or a pharmaceutically
15 acceptable salt or solvate thereof, as defined in claims 1 to 17.

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/003689

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07C317/22 C07C311/29 C07C255/54 C07C235/46 C07C59/66
C07C317/12 C07D213/71 C07D213/34 C07D207/06 C07D213/55
C07D265/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/058164 A2 (TULARIK INC [US]) 15 July 2004 (2004-07-15) claim 26; examples 8,9,19-24,38,71,73,77,78,83,84,89; table 1	1-21
A	US 2004/220237 A1 (FU ZICE [US] ET AL) 4 November 2004 (2004-11-04) the whole document	1-21
A	EP 0 540 165 A (ICI PHARMA [FR]; ICI PLC [GB]) 5 May 1993 (1993-05-05) corresponds to ep91402638 cited in the description the whole document	1-21
A	EP 0 114 734 A2 (UPJOHN CO [US]) 1 August 1984 (1984-08-01) the whole document	1-21

-/-

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search

20 February 2007

Date of mailing of the international search report

27/02/2007

Name and mailing address of the ISA/

European Patent Office, P.O. Box 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-0016

Authorized officer

Slootweg, Anita

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/003689

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 211 513 A1 (BML INC [JP]) 5 June 2002 (2002-06-05) the whole document -----	1-21
A	EP 1 471 057 A1 (BAYER HEALTHCARE AG [DE] ACTIMIS PHARMACEUTICALS INC [US]) 27 October 2004 (2004-10-27) the whole document -----	1-21
A	WO 2004/096777 A (BAYER HEALTHCARE AG [DE]; LY TAI-WEI [JP]; KORIYAMA YUJI [JP]; YOSHINO) 11 November 2004 (2004-11-11) the whole document -----	1-21
P,X	US 2005/239881 A1 (DUNN JAMES P [US] ET AL DUNN JAMES PATRICK [US] ET AL) 27 October 2005 (2005-10-27) compounds 68,104B,106B,108B,109B,115B,116B -----	1,5-14, 16
E	WO 2006/125596 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; AXFORD JAKE [GB]; BAETTIG) 30 November 2006 (2006-11-30) the whole document -----	1-21
A	WO 2004/089884 A (ASTRAZENECA AB [SE]; PAIRAUDEAU GARRY [GB]; RASUL RUKHSANA [GB]; THOM) 21 October 2004 (2004-10-21) the whole document -----	1-21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2006/003689**Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 19-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 19-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.

Continuation of Box II.2

The present claim 1 relates to an extremely large number of possible compounds. Support and disclosure in the sense of Article 6 and 5 PCT is to be found however for only a very small proportion of the compounds claimed, see especially the last three lines of page 87 of the description. The non-compliance with the substantive provisions is to such an extent, that the search was performed taking into consideration the non-compliance in determining the extent of the search of claim 1 (PCT Guidelines 9.19 and 9.23).

The search of claim 1 was restricted to those claimed compounds which appear to be supported and a generalisation of their structural formulae, that is to compounds in which E is oxygen.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/003689

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004058164	A2	15-07-2004	
		AU 2003297398 A1	22-07-2004
		BR 0317591 A	22-11-2005
		CA 2511214 A1	15-07-2004
		CN 1767823 A	03-05-2006
		EP 1585511 A2	19-10-2005
		IS 7907 A	22-06-2005
		JP 2006516143 T	22-06-2006
		KR 20050111314 T	24-11-2005
		MX PA05006701 A	30-03-2006
US 2004220237	A1	04-11-2004	NONE
EP 0540165	A	05-05-1993	
		JP 5221926 A	31-08-1993
		US 5298511 A	29-03-1994
EP 0114734	A2	01-08-1984	
		CA 1210767 A1	02-09-1986
		DE 3463654 D1	19-06-1987
		JP 59172469 A	29-09-1984
		US 4486593 A	04-12-1984
		ZA 8308825 A	25-07-1984
EP 1211513	A1	05-06-2002	
		AT 315230 T	15-02-2006
		AU 772121 B2	08-04-2004
		AU 6598800 A	19-03-2001
		CA 2383135 A1	01-03-2001
		DE 1211513 T1	14-11-2002
		DE 60025368 T2	14-09-2006
		WO 0114882 A1	01-03-2001
		JP 3486408 B2	13-01-2004
		NO 20020837 A	22-04-2002
		US 6884593 B1	26-04-2005
EP 1471057	A1	27-10-2004	
		AT 316077 T	15-02-2006
		AU 2004233966 A1	11-11-2004
		BR PI0409733 A	09-05-2006
		CA 2523439 A1	11-11-2004
		CN 1809539 A	26-07-2006
		DE 60303238 T2	14-09-2006
		DK 1471057 T3	15-05-2006
		WO 2004096777 A1	11-11-2004
		ES 2257616 T3	01-08-2006
		JP 2006524645 T	02-11-2006
		KR 20060089622 A	09-08-2006
		MX PA05011399 A	31-05-2006
		PT 1471057 T	31-05-2006
WO 2004096777	A	11-11-2004	
		AT 316077 T	15-02-2006
		AU 2004233966 A1	11-11-2004
		BR PI0409733 A	09-05-2006
		CA 2523439 A1	11-11-2004
		CN 1809539 A	26-07-2006
		DE 60303238 T2	14-09-2006
		DK 1471057 T3	15-05-2006
		EP 1471057 A1	27-10-2004
		ES 2257616 T3	01-08-2006
		JP 2006524645 T	02-11-2006
		KR 20060089622 A	09-08-2006
		MX PA05011399 A	31-05-2006

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/682006/003689

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004096777 A		PT 1471057 T	31-05-2006
US 2005239881 A1	27-10-2005	NONE	
WO 2006125596 A	30-11-2006	NONE	
WO 2004089884 A	21-10-2004	EP 1636175 A1	22-03-2006
		JP 2006522117 T	28-09-2006
		US 2006211765 A1	21-09-2006